Document:

Exhibit 10.26

 

Confidential Treatment Requested.

Confidential portions of this document have been redacted and have been filed separately with the Commission

 

Execution Copy

 

EX-U.S. CO-PROMOTION AGREEMENT

 

BETWEEN

 

Genzyme Corporation, with offices located at 500 Kendall Street, Cambridge, Massachusetts 02142 (hereinafter referred to as “Genzyme”)

 

and

 

Veracyte, Inc., with offices located at 7000 Shoreline Ct., Ste. 250, South San Francisco, CA 94080 (hereinafter also referred to as “Veracyte”)

 

WHEREAS

 

A.                                      Veracyte has developed the Afirma® Thyroid FNA Analysis, which includes centralized cytopathology and molecular testing services for the assessment of thyroid nodules;

 

B.                                      Genzyme is engaged in the business of and has expertise in, among other things, the sales and marketing of Thyrogen® (thyrotropin alfa for injection), a product for patients with thyroid cancer;

 

C.                                      Veracyte and Genzyme are currently promoting the Afirma Thyroid FNA Analysis in the United States (“U.S.”) pursuant to the Amended and Restated U.S. Co-Promotion Agreement, by and between Genzyme and Veracyte, dated as of November 7, 2014 (the “U.S. Co-Promotion Agreement”);

 

D.                                      Genzyme has professional endocrinology sales organizations outside the U.S.; and

 

E.                                       Veracyte and Genzyme desire to co-promote the Afirma Thyroid FNA Analysis in the Territories upon the terms and conditions set forth herein.

 

NOW, THEREFORE, in consideration of the mutual covenants and agreements set forth in this Agreement, and for other good and valuable consideration, the receipt and sufficiency of which is hereby acknowledged, the parties hereto agree as follows:

 

SECTION 1 - DEFINITIONS

 

1.1                               In the terms defined herein, the singular shall include the plural and vice versa.

 

“Ad/Prom Materials” shall mean advertising and promotional materials for the Test.

 

“Additional Country” shall have meaning set forth in Section 2.6.

 

“Affiliate” shall mean any entity that directly or indirectly controls, is controlled by or is under common control with another entity.  The term “control”, including the terms 

 

 

“controlled by” or “under common control with” means the possession of, directly or indirectly, the capability to control the direction of the management and policies of any entity, whether through the ownership of shares, by contract or otherwise.

 

“Afirma” shall mean Afirma Thyroid FNA Analysis.

 

“Agreement” shall mean this Ex-U.S. Co-Promotion Agreement and its Exhibits.

 

“Annual Commercial Plan” shall have the meaning set forth in Section 3.2.1.

 

“Call” shall mean a face-to-face visit by a direct professional sales representative of Genzyme or its Affiliates or Veracyte or its Affiliates to a Healthcare Professional for the purposes of promoting the Test.  For the avoidance of doubt, visits primarily related to complaints or otherwise primarily related to customer service shall not be deemed “Calls”.

 

“Call Obligations” shall have the meaning set forth in Section 3.1.2.

 

“CAPAs” shall have the meaning set forth in Section 4.8.2.

 

“Change of Control” shall mean that (i) any person/entity controlling a party ceases to control that party; (ii) any person/entity not controlling a party obtains control of that party; (iii) the acquisition, directly or indirectly, by any Person or group of related Persons (other than any Person that controls, is controlled by or is under common control with a party) of beneficial ownership (as such term is defined in Rule 13d-3 promulgated under the Securities Exchange Act of 1934, as amended) of securities possessing more than fifty percent (50%) of the total combined voting power of a party’s outstanding securities; (iv) a merger or consolidation in which securities possessing more than fifty percent (50%) of the total combined voting power of such party’s outstanding securities are transferred to a Person or Persons different from the Persons holding those securities immediately prior to such transaction; or (v) the sale, transfer or other disposition of all or substantially all of such party’s assets; provided, however, that in the case of Genzyme, if any of the foregoing occurs in connection with or as a result of reorganization or a transaction with Sanofi and/or another Affiliate, then it shall not be deemed a Change of Control for purposes of this Agreement.  The term “control”, including the term “controlling” means the possession of, directly or indirectly, the capability to control the direction of the management and policies of a party, whether through the ownership of shares, by contract or otherwise.  The term “Person” shall mean an individual, corporation, partnership, limited liability company, trust, business trust, association, joint stock company, joint venture, pool, syndicate, sole proprietorship, unincorporated organization, governmental authority, or any other form of entity not specifically listed herein.

 

“CLIA” shall have the meaning set forth in Section 4.1.1(d).

 

2

 

“Collection Kits” shall mean the sample collection and sample transport supplies intended for the collection and transport of human thyroid FNA samples for the Test, which may include, without limitation, collection tubes with preservation solution, slide holders, and sample shipment materials, as may be determined by Veracyte from time to time in a manner consistent with applicable laws and Marketing Authorizations.  For the avoidance of doubt, Collection Kits do not include syringes, needles or other devices for sample aspiration from patients or any other materials intended to come in physical contact with patients.

 

“Commercially Reasonable Efforts” shall mean that level of effort which would be devoted by an independent entity seeking to expeditiously and diligently pursue its own business efforts in light of relevant circumstances, but in no case less than that level of efforts and resources, in such a manner, and with such expedition as a party itself would adopt in launching, promoting and detailing its own services or products with similar market value or potential as the Test, taking into consideration all relevant considerations, including without limitation patent protection or trade secret protection.  For the avoidance of doubt, the aforementioned examples of relevant considerations are not intended to be exhaustive and no one such consideration (such as the absence of patents or trade secret protection in a particular Country alone) is intended to be determinative in and of itself of whether a party exercised the requisite level of diligence.

 

“Complaint” shall mean a written, electronic or oral communication or expression of dissatisfaction that alleges deficiencies related to the Test (including Improvements), including, without limitation, identity, quality, labelling, safety, accuracy or performance of the Test.

 

“Comprehensive Services Territory” shall mean any Additional Country designated as part of the Comprehensive Services Territory pursuant to Section 2.6.

 

“Confidential Information” shall mean all information not known to the general public or of a confidential nature disclosed (in writing, verbally, electronically, or by any other means directly or indirectly) by or on behalf of one party (the “Disclosing Party”) to the other party (the “Receiving Party”) under this Agreement, including, without limitation, any information relating to (i) the manufacture, testing, price, Complaints about (except as are required to be disclosed to Regulatory Authorities), Marketing Authorizations for, customers of, or defects in, the Test, (ii) a party’s inventions, discoveries, improvements, methods, products, finances, operations, processes, plans, product information (including new or prototype products), know-how, design rights, trade secrets, market opportunities, regulatory information, customer and supplier information and business affairs, and (iii) the provision of the Test.

 

“Contract Year” shall mean a twelve (12)-month period commencing as of January 1 and ending as of December 31.  For the purposes of this Agreement, the first contract year shall commence on the Effective Date and end on December 31, 2015.

 

“Country” shall mean any of the countries in the Territories.

 

3

 

“Country Commitment Date” shall mean, with respect to a Country, the “Country Commitment Date” set forth on Exhibit A for such Country.

 

“Country Payment Rate” shall mean, with respect to a Country, the “Country Payment Rate” set forth on Exhibit A for such Country.

 

“Country Regulatory Event” shall have the meaning set forth in Section 11.6.5(a).

 

“Country Regulatory Termination” shall have the meaning set forth in Section 11.6.1.

 

“Country Removal Notice” shall have the meaning set forth in Section 11.7.

 

“CRE Notice” shall have the meaning set forth in Section 11.6.1.

 

“CS Collection Activities” shall have the meaning set forth in Section 4.11.1.

 

“CS Royalty” shall have the meaning set forth in Section 6.1.1.

 

“Dedicated Promotion Only Territory” shall mean Brazil, Singapore, and any Additional Country designated as part of the Dedicated Promotion Only Territory pursuant to Section 2.6.

 

“DPO Collection Activities” shall have the meaning set forth in Section 4.11.2.

 

“DPO Promotion Fees” shall have the meaning set forth in Section 6.1.2.

 

“Effective Date” shall mean January 1, 2015.

 

“Extended Term” shall have the meaning set forth in Section 11.1.

 

“FCPA” shall have the meaning set forth in Section 9.5.1(a).

 

“FNA” shall mean fine needle aspiration biopsy(ies).

 

“Future Test” shall mean any product or service, other than the Test, and all improvements to such product or service, that Veracyte owns, controls or has rights to at any time during the Term, that (i) is/are for additional thyroid cancer diagnosis or treatment applications including, without limitation, tests developed on cytopathology diagnoses other than Indeterminate, and (ii) require(s) one or more additional clinical study(s) in order to obtain Marketing Authorization or, if Marketing Authorization is not required, to effectively compete in the market.  For purposes of clarity, Future Test does not include any product or service used outside of the field of thyroid cancer diagnosis and treatment, including, without limitation, the diagnosis or treatment of any other tissues, organs, or systems or any other diseases or conditions.

 

4

 

“GAAP” shall mean then-current international generally accepted accounting principles, consistently applied.

 

“Genzyme Detail Report” shall have the meaning set forth in Section 3.4.1.

 

“Genzyme Quarterly Net Revenue Report” shall have the meaning set forth in Section 6.2.1.

 

“Genzyme Trademarks” shall mean Trademarks of Genzyme.

 

“Healthcare Professionals” shall mean (i) health care providers qualified to prescribe, recommend, or perform diagnostic testing for thyroid cancer, in each case who are authorized by applicable law to authorize, utilize, or prescribe the Test and (ii) any associated staff who need to be educated about the Test (including without limitation logistics related to the Test), including but not limited to nurses, laboratory technicians, physician assistants, and administrative staff.

 

“Improvement(s)” shall mean any and all modifications, variations, revisions or other improvements to the Test that: (i) are not otherwise described in the Veracyte Intellectual Property as of the Effective Date; (ii) are made during the Term of this Agreement, by or on behalf of Veracyte, its Affiliates or any employees, consultants or other persons under Veracyte’s direction or control; and (iii) are commercialized or offered for sale by Veracyte or its Affiliates including, without limitation, any product or service sold under the name “Afirma”, during the Term of this Agreement in the Territory.  For purposes of clarity, Improvements shall not include Future Tests.

 

“Indeterminate” shall mean, as of the Effective Date, the following: follicular lesion of undetermined significance (FLUS)/atypia, follicular/Hürthle cell neoplasm or suspicious for follicular/Hürthle cell neoplasm, and suspicious for malignancy.  The definition of Indeterminate may be updated and amended in writing as reasonably determined by Veracyte in good faith, including based on applicable regulatory or clinical practice guidelines or market needs.

 

“Initial Term” shall have the meaning set forth in Section 11.1.

 

“Intellectual Property Rights” shall mean all rights, privileges and priorities provided under federal, state, foreign and multinational law relating to intellectual property, including without limitation all (i) (A) U.S. and foreign patents and patent applications, inventions, discoveries, machines, manufactures, compositions of matter, processes, formulae, designs, methods, techniques, procedures, concepts, developments, technology, new and useful improvements thereof and know-how relating thereto, whether or not patented or patentable; (B) copyrights and works of authorship, including computer applications, programs, software, hardware, files, mask works, compilations, databases, documentation and related items; (C) trademarks, service marks, trade names, domain names, URLs, email addresses, brand names, corporate names, logos and trade dress and the goodwill of any business symbolized thereby; (D) trade secrets, drawings, lists and all

 

5

 

other proprietary, nonpublic or confidential information, documents or materials in any media; and (ii) all registrations, applications, recordings and other legal protections or rights related to the foregoing.

 

“Labeled Uses” shall mean the diagnostic indications covered by the Marketing Authorization for the Test or, in the absence of any such Marketing Authorization in any Country, the supporting clinical documentation approved by Veracyte.

 

“Liabilities” shall have the meaning set forth in Section 10.1.1.

 

“Marketing Authorization” shall mean the regulatory authorization required to market and sell the Test in a Country, if any.

 

“Net Revenues” shall mean actual cash received (i) by Veracyte and its Affiliates from the sale of Tests in the Dedicated Promotion Only Territories and (ii) by Genzyme and its Affiliates from the sale of Tests in the Comprehensive Services Territory, including in each case ((i) and (ii)), but not limited to, cash paid on payor claims and out-of-pocket payments by patients.  For clarity, (a) Veracyte’s Test Processing Costs for the Test shall not be deducted in the calculation of Net Revenues, (b) any royalties, licensing fees, damages, or settlement costs paid in order to obtain or maintain rights to a third party’s Intellectual Property Rights, which rights are necessary or useful for using, processing, making or commercializing the Test, shall not be deducted in the calculation of Net Revenues, and (c) any costs or royalties (owed to a third party) associated with a third party’s performance of any part(s) of Veracyte’s or Genzyme’s responsibilities under this Agreement shall not be deducted in the calculation of Net Revenues.

 

“New Genzyme Product” shall have the meaning set forth in Section 3.1.3.

 

“Qualified Country Regulatory Event” shall have the meaning set forth in Section 11.6.5(b).

 

“Regulatory Authority” shall mean the authority or agency responsible for granting a Marketing Authorization or approving the provision and provider of the Test.

 

“Removed Country” shall mean a Country removed from the definition of Comprehensive Services Territory or Dedicated Promotion Only Territory in accordance with Section 11.6 or Section 11.7 hereof.

 

“ROFN Term” means, with respect to an ROFN Country, the period of time commencing on January 1, 2015 and extending until the earlier of December 31, 2017 or sixty (60) days after Veracyte informs Genzyme that it has successfully secured reimbursement from payors covering at least fifty (50%) of such country’s population.

 

“ROFN Agreement” shall have the meaning set forth in Section 2.5.

 

“ROFN Countries” means Canada, the Netherlands, and Italy.

 

6

 

“Steering Committee” shall have the meaning set forth in Section 5.1.

 

“Subject Products” shall mean Thyrogen and any New Genzyme Product, but excludes any Third Genzyme Product.

 

“Term” shall mean the Initial Term and the Extended Term, if any.

 

“Territories” shall mean the Comprehensive Services Territory and the Dedicated Promotion Only Territory together.

 

“Territory” shall mean either the Comprehensive Services Territory or the Dedicated Promotion Only Territory.

 

“Test” shall mean the Afirma service that includes the assessment of thyroid nodule FNAs by cytopathology and/or the assessment of cytopathology Indeterminate FNAs by the Afirma Gene Expression Classifier to reclassify the nodule as benign or suspicious for malignancy, including any Improvements thereto.  The term “Test” includes the utilization of the Collection Kits, preparation, analysis and reporting of patient results and for the avoidance of doubt does not include any devices used for sample aspiration from the patient.  Any second or subsequent generation of the Afirma service will be included in the definition of “Test”.

 

“Test Processing Costs” shall mean all direct and indirect costs incurred by Veracyte for activities associated with the collection of FNAs and processing (including, without limitation, direct costs associated with finishing processes such as packaging, labelling and other preparation, quality assurance, quality control, testing, storage and shipping) of the Test including, without limitation, costs of labor (including, but not limited to, salaries, bonuses, benefits and stock-based compensation), raw materials, supplies, services, license and royalty fees, costs associated with third party cytopathology laboratory services, and other resources directly consumed or used in the conduct of the applicable activity and any fees payable to any third party to the extent attributable to the collection of FNAs and processing of the Test, and all indirect costs including without limitation costs of indirect labor (including but not limited to salaries, bonuses, benefits and stock-based compensation), facilities, utilities, insurance, administrative costs, and facility and equipment depreciation and amortization, where applicable to the extent directly related to the applicable activity, allocated consistent with GAAP and as historically applied by Veracyte prior to the Effective Date of this Agreement.  All such cost determinations shall be made in accordance with GAAP and shall be supported by appropriate documentation.

 

“Third Genzyme Product” shall have the meaning set forth in Section 3.1.3.

 

“Thyrogen” shall mean Thyrogen® (thyrotropin alfa for injection) and any and all modifications, variations, revisions, uses or other improvements thereto.

 

7

 

“Trademarks” shall mean all registered trademarks, trademarks or trade names (whether or not appearing in large print or with the trademark symbol) of Genzyme and Veracyte and their respective Affiliates, licensors or joint venture partners, as applicable, listed on Exhibit B.  The use of these Trademarks or any other materials, except as permitted by this Agreement, is expressly prohibited and may be in violation of copyright law, trademark law or other proprietary rights of Genzyme or Veracyte.  Exhibit B shall be updated and amended by the parties in writing in the event that (a) Veracyte adopts a new Trademark for use in connection with Improvements or any Future Tests that is added to this Agreement pursuant to Section 2.4, (b) Genzyme adds an additional product to the portfolio pursuant to Section 3.1.3 and (c) either party uses a new Trademark for the portion of its business operations related to the co-promotion of the Test.

 

“U.S.” shall have the meaning set forth in the recitals.

 

“U.S. Co-Promotion Agreement” shall have the meaning set forth in the recitals.

 

“Veracyte Intellectual Property” shall mean any and all Intellectual Property Rights exclusively or non-exclusively (with the right to grant sublicenses) owned or controlled by Veracyte or its Affiliates during the Term that are required for Genzyme to carry out its obligations to promote, market and detail the Test under this Agreement.  For the avoidance of doubt, Veracyte Intellectual Property includes any Intellectual Property Rights related to Improvements required to promote, market and detail any such Improvements to the Test.  The Veracyte Intellectual Property includes the patents and patent applications identified in Exhibit C, as well as any patent or patent application that claims priority to any such patent or patent application and any foreign counterparts of any of the foregoing. Veracyte shall promptly update Exhibit C from time to time as appropriate to list any additional patents and patent applications that existed as of the Effective Date but were not included in Exhibit C (if any) or are conceived, developed or acquired by or on behalf of Veracyte or its Affiliates after the Effective Date that constitute Veracyte Intellectual Property.

 

“Veracyte Owned Intellectual Property” shall mean any and all Veracyte Intellectual Property exclusively owned or controlled by Veracyte including the patents and patent applications indicated on Exhibit C, as well as any patent or patent application that claims priority to any such patent or patent application and any foreign counterparts of any of the foregoing.

 

“Veracyte Quarterly Net Revenue Report” shall have the meaning set forth in Section 6.2.2.

 

“Veracyte Trademarks” shall mean Trademarks of Veracyte.

 

8

 

SECTION 2 - GENERAL ARRANGEMENTS

 

2.1                               Grant of Rights.

 

2.1.1                     Comprehensive Services.  Subject to the terms of this Agreement and subject to Veracyte’s retained rights under Section 2.1.3, Veracyte hereby grants to Genzyme and its Affiliates (to the extent such Affiliates are promoting, marketing, detailing and selling the Test hereunder), on an exclusive (even as to Veracyte) basis in the Comprehensive Services Territory, the right and license under the Veracyte Intellectual Property to promote, market, detail, sell, offer for sale the Test and to sell, offer for sale and import the Collection Kits in the Comprehensive Services Territory during the Term and to conduct its obligations under this Agreement as permitted under and subject to the terms and conditions set forth in this Agreement.

 

2.1.2                     Dedicated Promotion Only.  Subject to the terms of this Agreement and subject to Veracyte’s retained rights under Section 2.1.3, Veracyte hereby grants to Genzyme and its Affiliates (to the extent such Affiliates are promoting, marketing and detailing the Test hereunder), on a co-exclusive (with Veracyte) basis in the Dedicated Promotion Only Territory, the right and license under the Veracyte Intellectual Property to promote, market and detail the Test in the Dedicated Promotion Only Territory during the Term and to conduct its obligations under this Agreement as permitted under and subject to the terms and conditions set forth in this Agreement.

 

2.1.3                     Retained Rights.  Notwithstanding anything contained herein, or elsewhere, to the contrary, the license grant to Genzyme and its Affiliates (to the extent such Affiliates are granted a license grant pursuant to Section 2.1.1 or Section 2.1.2) is expressly made subject to Veracyte’s reservation of the right to promote, market, detail, make, have made, use, sell, offer for sale, import and export the Test in the Dedication Promotion Only Territory.  Except as expressly set forth hereunder, nothing in this Agreement shall be construed to grant to Genzyme or its Affiliates by implication, estoppel or otherwise any licenses under Intellectual Property Rights owned or controlled by Veracyte other than the Veracyte Intellectual Property.

 

2.2                               Use of Trademarks.

 

2.2.1                     Veracyte hereby grants to Genzyme and its Affiliates a non-exclusive, royalty-free right and license to use the Trademarks of Veracyte solely in connection with performing its obligations hereunder.  Genzyme hereby grants to Veracyte and its Affiliates a non-exclusive, royalty-free right and license to use the Trademarks of Genzyme solely in connection with performing its obligations hereunder.  Genzyme and its Affiliates may use the Veracyte Trademarks on leaflets, brochures, advertising and other promotional material that describe the Test and products promoted, marketed and detailed by the Genzyme sales force promoting the Test.  Veracyte and its Affiliates may use the Genzyme Trademarks on

 

9

 

leaflets, brochures, advertising and other promotional and sales materials that describe the Test and products promoted by the Genzyme sales force promoting the Test.  Notwithstanding the foregoing, any usage of a party’s Trademarks by the other party must be approved in advance by the party who owns the Trademarks, such approval not to be unreasonably withheld, delayed, or conditioned.  It is understood and agreed that neither party shall use the other party’s Trademarks in Test labeling (which includes without limitation Collection Kit packaging, labels and package inserts, laboratory requisitions, and patient report forms) unless otherwise required by applicable laws and regulations (in which case the prior approval must still be obtained for such usage pursuant to the immediately preceding sentence).

 

2.2.2                     Each party shall use the Trademarks only for the purposes authorized hereunder and, in particular, shall not use the Trademarks in a manner that would reduce or diminish the reputation, image and distinctiveness of the Trademarks.

 

2.2.3                     Neither party shall, by virtue of this Agreement, obtain or claim any right, title or interest in or to the Trademarks of the other party, except the rights of use as are specifically set out herein, and each party hereby acknowledges and agrees that the goodwill arising from such use shall at all times inure for the benefit of the existing owner of the Trademark.

 

2.2.4                     Neither party shall adopt or use any trademark, symbol or device which includes or which is confusingly similar to, or is a simulation or colorable imitation of, any of the Trademarks.  Neither party shall apply to register the Trademarks or any trademark so nearly resembling them or any of them as may be likely to cause confusion and nothing in this Agreement shall be deemed to give either party any such right.

 

2.2.5                     Each party shall, promptly upon written request by the other party, submit to the requesting party samples of any packaging, leaflets, brochures, advertising, promotional material and any other material relating to the Test necessary in order to monitor such party’s compliance with its obligations hereunder.  Each party shall use the other party’s Trademarks in such font, form, color, size or other representation as are promptly approved in writing by such other party (such approval not to be unreasonably withheld, conditioned or delayed).

 

2.2.6                     Nothing in this Agreement shall entitle Genzyme or Veracyte to use the other party’s Trademarks as part of any corporate business or trading name or logo or to use the Trademarks or any marks which are similar to the Trademarks in respect of any goods which are similar to the Test without the express written consent of the other party.

 

2.2.7                     Each party shall ensure that whenever it uses the Trademarks of the other party, the party shall use Commercially Reasonable Efforts to ensure that such Trademarks accompanied by the appropriate wording and symbols (® or TM) necessary to either show that the Trademarks are registered trademarks or

 

10

 

trademarks, as the case may be, of the other party or to otherwise protect such Trademarks.

 

2.2.8                     Genzyme shall give Veracyte prompt written notice of any infringement or threatened infringement of any Trademarks of Veracyte used in connection with this Agreement that it becomes aware of, and Veracyte shall give Genzyme prompt written notice of any infringement or threatened infringement of any of the Trademarks of Genzyme used in connection with this Agreement that it becomes aware of.  Veracyte shall determine in its sole discretion what action, if any, to take in response to the infringement or threatened infringement of any Veracyte Trademark.  Genzyme shall determine in its sole discretion what action, if any, to take in response to the infringement or threatened infringement of any Genzyme Trademark.

 

2.3                               Covenants Not to Compete.

 

2.3.1                     During the Term of this Agreement, Genzyme and its Affiliates (including, without limitation, Sanofi) shall not, directly or indirectly, market, promote, detail, perform or process for commercial use, sell or offer for sale, import or commercialize any diagnostic test, diagnostic service, or diagnostic product in any country in the world that is either for the assessment of thyroid nodules, or that otherwise competes with the Test (or any Improvements thereto) in any way.  For the avoidance of doubt, this Section 2.3.1 shall not prohibit Genzyme or its Affiliates (including, without limitation, Sanofi), from marketing, promoting, selling, offering to sell, importing or commercializing Thyrogen.

 

2.3.2                     During the Term of this Agreement, Veracyte and its Affiliates shall not, directly or indirectly, market, promote, detail, perform or process for commercial use, sell or offer for sale, import or commercialize any test, service, or product in any country in the world that competes with Thyrogen:

 

(a)                                 in Thyrogen’s labelled indications described below,

 

(b)                                 as a therapy for treating multinodular goiter or

 

(c)                                  in any future labeled indications for Thyrogen approved by the regulatory authorities for such country (with it being understood that if Veracyte or any of its Affiliates directly or indirectly conducts research, product development, or clinical studies, or otherwise markets, promotes, details, performs or processes for commercial use, sells or offers for sale, imports or commercializes any test, product or service for an indication (other than solely for multinodular goiter) that is not an approved labelled indication for Thyrogen at the time Veracyte or its Affiliate, as the case may be, has commenced such activities and such indication is subsequently included in the approved labelled uses for Thyrogen, then Veracyte or its Affiliates, as the case may be, may continue such activities without being deemed to be in violation of this Section 2.3.2).

 

11

 

Thyrogen is indicated for use as (i) an adjunctive diagnostic tool for serum thyroglobulin (Tg) testing with or without radioiodine imaging in the follow-up of patients with well-differentiated thyroid cancer and (ii) an adjunctive treatment for radioiodine ablation of thyroid tissue remnants in patients who have undergone a near-total or total thyroidectomy for well-differentiated thyroid cancer and who do not have evidence of metastatic thyroid cancer.  For the avoidance of doubt, Veracyte’s obligations under this Section 2.3.2 shall include commercial substitutes for Thyrogen (including without limitation low functional sensitivity assays, any form of recombinant thyroid stimulating hormones or modified formulations thereof) whether or not the labeled use for such substitute overlaps with the then-current Thyrogen label.  It is understood and agreed that this Section 2.3.2 shall not prohibit Veracyte or its Affiliates from marketing, promoting, selling, offering to sell, importing or commercializing (A) the Test or (B) any Future Test that does not directly compete with Thyrogen as described above.

 

2.4                               Right of First Offer.  If during the Term of the Agreement (i) Veracyte owns or controls a Future Test and (ii) Veracyte decides to commercialize such Future Test in any Country, Veracyte will offer Genzyme the first opportunity to obtain the right to co-promote such Future Test in such Country.  In such case, the following procedure shall apply:

 

2.4.1                     Within ten (10) business days after its decision under Section 2.4(ii) above, Veracyte shall invite Genzyme in writing to enter into negotiations, setting forth, in such invitation, Veracyte’s proposed terms for co-promotion of the Future Test and any and all information about such Future Test as is reasonably requested by Genzyme;

 

2.4.2                     If Genzyme wishes to enter into such negotiations, Genzyme shall, within thirty (30) calendar days following receipt of Veracyte’s invitation, deliver to Veracyte written notice of Genzyme’s intent to negotiate for rights to said Future Test.  Promptly after receipt of such notice, the parties shall commence good faith negotiations exclusively with each other for a period not to exceed one hundred twenty (120) calendar days after the date Genzyme gives the requisite notice to Veracyte (unless extended by mutual written agreement of the parties); and

 

2.4.3                     If Genzyme does not deliver to Veracyte written notice of its intent to negotiate for such rights within such thirty (30) calendar day period, then Veracyte shall be free to negotiate and enter into a co-promotion agreement or similar agreement for the relevant Future Test and Country with any third party unless such Future Test directly competes with Thyrogen as described in Section 2.3.2 above.

 

2.4.4                     If Veracyte and Genzyme do not enter into a legally binding, written agreement within the said one hundred twenty (120) calendar day period (and such period has not been extended by mutual written agreement of the parties), Veracyte shall be free to negotiate and enter into a co-promotion agreement or similar agreement for the relevant Future Test and Country with any third party on terms (considered as a whole) not materially more favorable than the one last offered to Genzyme

 

12

 

unless such Future Test directly competes with Thyrogen as described in Section 2.3.2 above.

 

2.4.5                     It is the understanding of the parties that the following transactions shall not be subject to the Right of First Offer described in this Section 2.4:  (i) any Change of Control transaction involving Veracyte, including any proposed merger, acquisition, or sale of all or substantially all the assets of Veracyte; or (ii) any bona fide financing transaction for Veracyte.

 

2.5                               Right of First Negotiation.  During the ROFN Term, with respect to an ROFN Country, Genzyme will have an exclusive right of first negotiation to enter into an agreement with Veracyte governing the terms and conditions of the sale and provision of the Test in such ROFN Country (the “ROFN Agreement”), including by adding such ROFN Country to the Territories of this Agreement in accordance with Section 2.6. Genzyme may exercise such right with respect to an ROFN Country by delivering written notice thereof to Veracyte within the ROFN Term for such country. If Genzyme timely exercises such right with respect to an ROFN Country, then the parties will promptly negotiate exclusively, diligently and in good faith concerning the terms of the ROFN Agreement for a period of ninety (90) days. If (a) Genzyme does not exercise its right of first negotiation with respect to an ROFN Country during the ROFN Term or (b) the parties fail to execute an ROFN Agreement for such ROFN Country, then Veracyte will be free to enter into an agreement with a third party governing the terms and conditions of the sale and provision of the Test in such ROFN Country. Commencing on the Effective Date and extending until (i) Genzyme does not exercise its right of first negotiation with respect to an ROFN Country during the ROFN Term; (ii) an ROFN Agreement is executed or (iii) the parties fail to execute an ROFN Agreement, as applicable, Genzyme will share with Veracyte client and marketing information related to the ROFN Countries. Notwithstanding the foregoing, Veracyte will have the right to request, in writing, that Genzyme exercise its right of first negotiation with respect to Singapore before Veracyte informs Genzyme that it has successfully secured reimbursement from payors representing at least fifty percent (50%) of Singapore’s population. If Genzyme (1) does not agree to exercise its right of first negotiation within respect to Singapore within sixty (60) days of its receipt of such request from Veracyte, or (2) exercises such right but the parties fail to execute an ROFN Agreement for Singapore within ninety (90) days of such exercise, then Veracyte will be free to enter into an agreement with a third party governing the terms and conditions of the sale and provision of the Test in Singapore.

 

2.6                               Additional Countries.  From time to time, the parties may add additional countries other than the U.S. to the Territories of this Agreement by written agreement (each, an “Additional Country”).  Each such written agreement shall contain (i) the designation of the Additional Country as part of the Comprehensive Services Territory or Dedicated Promotion Only Territory, (ii) an amendment to Exhibit A containing the Country Payment Rate, Country Commitment Date for such Additional Country and any additional Country-specific terms and conditions as the Parties may agree, and (iii) an amended Annual Commercial Plan for the then-current calendar year which shall supersede the Annual Commercial Plan then in effect.  In the event of any conflict

 

13

 

between the terms and conditions in the body of this Agreement and Exhibit A, Exhibit A will control.

 

SECTION 3 — GENZYME’S UNDERTAKINGS

 

3.1                               Genzyme’s Roles and Responsibilities.

 

3.1.1                     Genzyme’s Sales Efforts and Activities.  Subject to the provisions of and during the Term of this Agreement, Genzyme and, to the extent any of its Affiliates employ sales and marketing personnel used to promote, market, sell, or detail Thyrogen, or otherwise promotes, markets, sells, or details Thyrogen, such Affiliates shall use Commercially Reasonable Efforts to 
 (a) market, promote, detail and sell the Test to Healthcare Professionals for the Labeled Uses (if and as applicable) in the Comprehensive Services Territory in accordance with the then-current Annual Commercial Plan and (b) market, promote and detail the Test to Healthcare Professionals for the Labeled Uses (if and as applicable) in the Dedicated Promotion Only Territory in accordance with the then-current Annual Commercial Plan.  Genzyme shall reasonably consider any input provided by Veracyte regarding such activities.

 

3.1.2                     Call Position.  During Calls, in addition to the Test, Subject Products may be presented, but the promotional message involving the Test must be presented in a substantive manner in the first, second or third position (the “Call Obligations”).  At such time as Genzyme begins marketing, promoting and detailing the Test in any Country in accordance with the then-current Annual Commercial Plan and for the remainder of the Term of this Agreement, Genzyme and its Affiliates shall observe the Call Obligations on Calls conducted by their respective sales forces used to promote Thyrogen in such Country unless otherwise agreed by Veracyte in writing in its sole discretion.

 

3.1.3                     New Genzyme Products.  It is acknowledged by the parties that Genzyme has stated that it intends to use its and its Affiliates’ sales and marketing personnel that promote, market and detail Thyrogen to promote, market and detail another Genzyme product, in accordance with and subject to the terms and conditions of this Agreement after it receives marketing approvals from the Regulatory Authorities (any such product so promoted by such sales force, a “New Genzyme Product”).  If, at any time during the Term, Genzyme desires to add a product other than the New Genzyme Product (a “Third Genzyme Product”) to the portfolio of products promoted by the sales force that is promoting, marketing and detailing the Test and Thyrogen (other than pursuant to Section 2.4), Genzyme will obtain Veracyte’s written consent to add such Third Genzyme Product to the portfolio as soon as practicable prior to doing so; provided, however, that if (a) such product is in the field of thyroid cancer, (b) the addition of such product would not affect Genzyme or its Affiliates’ ability to comply with its obligations under this Agreement, and (c) the addition of such product would not otherwise violate the terms and conditions of this Agreement, then Veracyte shall not unreasonably withhold, delay or condition its consent.

 

14

 

3.1.4                     Compliance.  In performing their duties hereunder, Genzyme and its Affiliates shall, and shall cause their respective employees and agents who perform activities related to the Test to, comply with all reasonable policies and directives issued by Veracyte from time to time with respect to the Test (provided that such polices and directives are compliant with applicable local laws and regulations, the Labeled Uses and the Marketing Authorizations) and with all applicable regulatory, professional and legal requirements which may be applicable to the services to be provided by Genzyme hereunder.  Neither Genzyme nor its Affiliates, nor any of their respective employees or agents, shall make any claim, representation, statement, warranty or guaranty with respect to the Test that is inconsistent with the then current Labeled Uses of the Test, this Agreement or the Ad/Prom Materials approved by the Steering Committee, that is deceptive or misleading or that disparages the Test or the good name, goodwill and reputation of Veracyte.  Genzyme and its Affiliates shall use Commercially Reasonable Efforts to ensure that any services provided hereunder will be provided in a professional, ethical and competent manner.

 

3.1.5                     Account Management.  Except as otherwise provided in Exhibit A, Genzyme shall be solely responsible for Healthcare Professional account conversion and set-up, account management and account support in the Territories.

 

3.1.6                     Sampling Program.  Except as otherwise provided in Exhibit A, Genzyme shall manage and provide a sampling program for the Test in which Genzyme will provide Collection Kits to Healthcare Professionals in the Territories in accordance with the Annual Commercial Plan.  The Steering Committee shall determine the number of Collection Kits that Genzyme shall purchase from Veracyte for use in such sampling program at a price equal to Veracyte’s Test Processing Costs for conducting the Test with such Collection Kits.

 

3.1.7                     Medical Staff Access.  Genzyme shall provide Healthcare Professionals and representatives of payors utilizing the Test with reasonable access to Genzyme’s medical and healthcare personnel to discuss scientific and clinical aspects of the Test and its applicability to patients.

 

3.1.8                     Costs.  Genzyme shall be solely responsible for the costs and expenses of establishing and maintaining Genzyme’s and its Affiliates’ sales force (including travel related costs), and conducting its other activities under this Agreement; provided, however, that the training of such sales force shall be conducted in accordance with Section 4.3.

 

3.1.9                     Review of Promotional and Training Materials.  To the extent practicable, all promotional and training materials provided to any of Genzyme’s or its Affiliates’ sales representatives regarding strategy, positioning or selling messages for the Test will be subject to review and approval by the Steering Committee.  At any time during the Term, the Steering Committee may delegate a representative from each party to assume the responsibilities set forth in this Section 3.1.9.

 

15

 

3.2                               Annual Commercial Plan.

 

3.2.1                     Before April 1st of each calendar year commencing in the year 2015, Genzyme and Veracyte shall jointly submit an initial draft of a commercial plan for the Territories for the subsequent calendar year (each, an “Annual Commercial Plan”) to the Steering Committee for review and comment.  Before October 1st of each calendar year commencing in the year 2015, Genzyme and Veracyte shall jointly submit a final draft of the Annual Commercial Plan for the subsequent calendar year to the Steering Committee for approval.  Before November 15th of each calendar years commencing in 2015, the Steering Committee shall approve the final Annual Commercial Plan for the subsequent calendar year.  Within ninety (90) days after the Effective Date, the Steering Committee shall approve the Annual Commercial Plan for the calendar year commencing on January 1, 2015.

 

3.2.2                     The Annual Commercial Plan will specify in reasonable detail all marketing and promotional activities that Genzyme (and, where applicable, Veracyte) will undertake in each Country during the relevant calendar year.  The Annual Commercial Plan shall include, without limitation, the following: (a) Test positioning, strategy and tactics with regard to reimbursement efforts and with regard to supporting advertising and promotional activity to be undertaken; (b) a determination of the Healthcare Professional accounts that are appropriate and are not appropriate for Calls; (c) any training programs to be conducted; (d) medical and education programs to be conducted; (e) professional and trade relations activities; (f) any information to be specifically included in any Genzyme Detail Report; (g) specifications for the development of promotional and training materials (including the specific types of such materials to be developed); (h) projections for rebates and discounts for the Test; (i) such other information relating to the marketing and sales of the Test as deemed advisable by the Steering Committee; (j) the projected budget for all of the activities and materials anticipated under such plan, including without limitation projected gross billings and Net Revenues (in each case for both cytopathology and the molecular testing), projected billing rates by payor, and a breakdown of the projected costs for the activities and materials anticipated under the Annual Commercial Plan; and k) a three (3) year rolling sales forecast.  Neither party shall make any material change in any previously approved Annual Commercial Plan without the prior written approval of the Steering Committee.

 

3.3                               Sales Force.  Genzyme and its Affiliates shall directly employ a sufficient number of suitably qualified and trained personnel to ensure the fulfilment of Genzyme’s obligations including reimbursement efforts under this Agreement, as provided in Exhibit A.  Genzyme will promptly notify Veracyte in writing of any material proposed or of any actual changes to the sales personnel responsible for promoting the Test hereunder.

 

3.4                               Reporting.

 

3.4.1                     Genzyme shall provide Veracyte with a written report, within thirty (30) days of the end of each calendar quarter, detailing the efforts of its and its Affiliates’ sales

 

16

 

forces in promoting, marketing and detailing the Test during the preceding calendar quarter (or part thereof) for the Territories (the “Genzyme Detail Report”).  Such reports shall include the following information:

 

(a)                                 reimbursement discussions;

 

(b)                                 in the case of Countries in the Comprehensive Services Territory, billing information; and

 

(c)                                  such further information as agreed upon by the parties.

 

All such information shall be the Confidential Information of Genzyme and shall be maintained by Veracyte in accordance with Section 7 hereof.

 

3.5                               Advertising and Promotional Materials; Medical Affairs.

 

3.5.1                     Ad/Prom Materials.  All Ad/Prom Materials authorized by the Steering Committee pursuant to Section 5.2.2 shall be created and developed by Veracyte, and Veracyte shall reasonably consider any input provided by the Steering Committee or Genzyme.  Neither party may use any Ad/Prom Materials in the Territories that have not been previously approved by the Steering Committee or it’s designees pursuant to Section 5.2.2.  At its sole cost and expense during the Term, Genzyme shall (i) produce, print and distribute all such Ad/Prom Materials for Countries in the Territories, based on English language content developed by Veracyte, and in accordance with Genzyme’s reasonable policies and procedures and (ii) translate and adapt for local markets any such Ad/Prom Materials as appropriate for any Countries in the Territories without Steering Committee approval; provided, however, that copies of any such translated and adapted materials will be promptly provided to the Steering Committee.  Genzyme shall reasonably consider any input provided by the Steering Committee or Veracyte regarding such materials for future productions and printings of such materials.  In the event that the Steering Committee does not approve a particular type or form of Ad/Prom Material under Section 5.2.2 but one party still desires to create such type or form of material, such party may do so at it sole expense; provided, however, that such party must obtain Steering Committee review and approval of such Ad/Prom Material prior to any use thereof.  All Ad/Prom Materials produced by Genzyme under this Agreement are and shall remain the property of Genzyme; provided, however, that as between the parties hereto and except as expressly provided otherwise elsewhere in this Agreement, Veracyte shall exclusively own all right, title and interest in all Intellectual Property Rights in all Ad/Prom Materials, except for any content specifically related to Thyrogen or other Genzyme products and any Genzyme Trademarks (which shall be exclusively owned by Genzyme), and Genzyme shall have a royalty-free right and license under such Intellectual Property Rights during the Term.

 

3.5.2                     Observers.  Each party shall have the right to have an employee participate as an observer in the other party’s promotional review committee or board meetings

 

17

 

related to the Ad/Prom Materials; provided, however, that each party shall retain sole discretion regarding the management and scheduling of its promotional review committees or boards and the availability of the observer shall not influence the scheduling and timing of such meetings.

 

3.5.3                     Talks and Grants.  In its sole discretion, Genzyme will (i) participate in speaker training events (at its sole cost and expense), (ii) participate in, and promote the Test at, key symposia, industry events and educational dinner programs as described in the Annual Commercial Plan (at its sole cost and expense) and (iii) provide grants to patient organizations, continuing medical education providers, and other appropriate recipients (at its sole cost and expense).  As between the parties hereto and except as expressly provided otherwise elsewhere in this Agreement, Veracyte shall develop all slide decks and promotional materials (including booth design for symposia and industry events) in the English language to be used by Genzyme for the above activities and shall exclusively own all right, title and interest in any such slide presentations except for any content specifically related to Thyrogen or other Genzyme products and any Genzyme Trademarks (which shall be exclusively owned by Genzyme).  Genzyme may modify such materials with prior written approval of the Steering Committee; provided, however, that Genzyme and its Affiliates may translate and adapt for local markets any such materials as appropriate for any Countries in the Territories without Steering Committee approval; provided further that copies of any such translated and adapted materials will be promptly provided to the Steering Committee; and provided further that Genzyme shall be solely responsible for the costs and expenses of and, to the extent directly related to the accuracy of such translations and adaptations, liabilities directly arising from, any such translations and adaptations.

 

3.5.4                     Physician Speaking Events.  If the Steering Committee determines that holding a physician speaker event will be advantageous to the promotion, marketing or sales of the Test in a Country that is a Comprehensive Services Territory, Genzyme shall pay for the honoraria and travel expenses of an academic-center based physician with expertise on the Test to provide a physician speaker event in such Country, and Veracyte shall pay such expenses if the Country is a Dedicated Promotion Only Territory.

 

3.5.5                     Veracyte shall pay for the honoraria and travel expenses of an academic-center based physician with expertise on the Test to provide a physician speaker event in such Country.

 

3.6                               Customer Support, Complaints and Inquiries.

 

3.6.1                     Customer Support.  In the Territories, Veracyte shall have sole responsibility for direct, front-line customer support including, without limitation, medical information support.  Veracyte shall perform these activities in a manner consistent with the responsibilities outlined in Exhibit D hereto.  Such activities shall be at Veracyte’s cost and expense.  Veracyte shall reasonably consider any

 

18

 

input provided by Genzyme regarding such customer support.  Genzyme shall provide reasonable support and assistance to Veracyte as reasonably requested at Veracyte’s cost and expense, subject to the availability of such resources.  In the Territories, Genzyme shall refer any requests or inquiries directly to Veracyte.

 

3.6.2                     Complaints.

 

(a)                                 If Genzyme or any of its Affiliates becomes aware of any Complaint or concern regarding the Test (including, without limitation, accuracy, quality or performance of the Test or any complaints or concerns regarding the sales, promotion, or marketing of the Test), Genzyme shall submit a written report of such Complaint or concern, along with any documentation involved with the Complaint, if available, to Veracyte within two (2) business days after receipt of such notice by Genzyme.  As between the parties, Veracyte shall have the sole authority and responsibility to respond to any governmental agency or Regulatory Authority to respond to Complaints, and to handle all returns field alerts, recalls or market withdrawals of the Test in accordance with applicable law; provided, however, that the foregoing shall not be construed to prevent Genzyme or its Affiliates in any way from complying with any governmental agency or Regulatory Authority or applicable laws, rules or regulations or from responding to governmental agencies or Regulatory Authorities with respect to Complaints regarding the conduct of Genzyme’s or its Affiliates’ sales force or the portion of any content of Ad/Prom Materials related to Genzyme’s or its Affiliates’ products.

 

(b)                                 Genzyme or its Affiliates shall forward all Complaints and inquiries to Veracyte in a timely manner as set forth in Section 3.6.2(a) hereof and shall follow any reasonable and timely directions Veracyte may provide in that respect including, without limitation, to allow Veracyte to comply with applicable local laws and regulations in the Territories.  If an investigation by Veracyte is needed in response to a Complaint or inquiry, Genzyme and its Affiliates shall assist Veracyte as reasonably requested by Veracyte and Veracyte shall forward the results of the investigation to Genzyme within a reasonable timeframe to allow Genzyme to comply with applicable local laws and regulations in a relevant Country.  Genzyme and its Affiliates shall retain records of all Complaints and inquiries for a period of not less than three (3) years beyond the expiration or termination date of this Agreement or for such longer period as may be required by applicable law.

 

3.7                               Audit.  Upon reasonable prior written notification, either party shall, during regular business hours, provide authorized representatives of the other party with access to its facilities (including those owned or operated by a third party), systems, personnel, books and records (including books and records regarding Net Revenues) as reasonably necessary to enable the representatives to audit such party’s compliance with its duties and responsibilities under this Agreement.  Each party shall be limited to one (1) audit

 

19

 

per Contract Year during the Term and once during the three (3) year period following the expiration or termination of this Agreement.  The records and Net Revenue reports for any particular calendar quarter may not be examined under this Section 3.7 more than once.

 

3.8                               Non-solicitation.  Neither party shall, directly or indirectly, take any action to cause the other party to lose any of its employees, agents, customer contacts or other elements of its goodwill; provided, however, that the foregoing shall not apply with respect to (i) any person as to whom conversations were initiated by such party after such person terminated his or her employment with the other party, (ii) any public advertisement in any general or industry publication, or (iii) any solicitation made through a recruiting or search firm retained by such party using a database of candidates without targeting the other party or specific individuals.

 

3.9                               Performance by Genzyme Affiliates.  Notwithstanding anything to the contrary contained in this Agreement, any Genzyme obligation hereunder may be assumed and performed by one or more of its Affiliates, and Genzyme may, at its election, delegate to any one or more of its Affiliates any duty or responsibility set forth in this Agreement; provided that Genzyme shall remain responsible for any and all acts and omissions by such Affiliate(s) to the same extent as if such were performed, taken or made by Genzyme.  In the event that Genzyme desires to perform its obligations in any Country through distributors (rather than through direct employees), Genzyme may make a written proposal to Veracyte for its consideration and if Veracyte agrees, (i) the parties will memorialize such agreement in writing and (ii) Genzyme shall remain responsible for any and all acts and omissions by such distributor to the same extent as if such were performed, taken or made by Genzyme.

 

SECTION 4 — VERACYTE’S UNDERTAKINGS

 

4.1                               Veracyte Roles and Responsibilities.

 

4.1.1                     Veracyte Test Processing Efforts.  Subject to the provisions of, and during the Term of, this Agreement, Veracyte and its Affiliates shall use Commercially Reasonable Efforts to offer and provide the Test beginning on the Effective Date in accordance with the then-current Annual Commercial Plan in the Countries in the Territories.  This means, among other things, that Veracyte and its Affiliates shall use their respective Commercially Reasonable Efforts:

 

(a)                                 to conduct and process the Test in accordance with the Test specifications, including without limitation as contained in the applicable Marketing Authorization (if any);

 

(b)                                 to handle and process all aspects of the Tests including receipt of Collection Kits, processing samples, and issuing patient reports;

 

(c)                                  to provide all central lab testing and processing required for provision of the Test and communicating Test results; and

 

20

 

(d)                                 to obtain and maintain all licenses, permits and certifications required to perform the foregoing responsibilities, including without limitation Clinical Laboratories Improvements Amendments (“CLIA”) certification, and ensure that any third party laboratories used by Veracyte to perform such responsibilities also have the requisite licenses, permits and certifications at all times while performing services on behalf of Veracyte.

 

4.1.2                     Test Terms of Sale.

 

(a)                                 Comprehensive Services.  Genzyme shall have the right to establish and modify (in its sole right and responsibility) terms and conditions regarding the sale and provision of the Test in each Country in the Comprehensive Services Territory, including the price of the Test will be sold, any discounts offered or applied, the availability of the Test, and contracting; provided, however, that all matters relating to pricing of the Test will be discussed by the Steering Committee and Veracyte’s input will be reasonably considered by Genzyme. Dedicated Promotion Only.  Veracyte shall have the right to establish and modify (in its sole right and responsibility) terms and conditions regarding the sale and provision of the Test in each Country in the Dedicated Promotion Only Territory, including the price of the Test will be sold, any discounts offered or applied, the availability of the Test, and contracting; provided, however, that all matters relating to pricing of the Test will be discussed by the Steering Committee and Genzyme’s input will be reasonably considered by Veracyte.

 

4.2                               Advertising and Promotional Materials; Medical Affairs.

 

4.2.1                     Compliance.  Veracyte and its Affiliates shall, and shall cause their respective employees and agents to, comply with all applicable regulatory, professional and legal requirements which may be applicable to Veracyte’s and its Affiliates’ marketing, promotion, and detail of the Test and its other obligations hereunder.  Neither Veracyte nor its Affiliates, nor any of their respective employees or agents, shall make any claim, representation, statement, warranty or guaranty with respect to the Test that is inconsistent with the then current Labeled Uses of the Test, this Agreement or the Ad/Prom Materials approved by the Steering Committee, that is deceptive or misleading or that disparages the Test or the good name, goodwill and reputation of Genzyme.  Veracyte and its Affiliates shall use Commercially Reasonable Efforts to ensure that any services provided hereunder will be provided in a professional, ethical and competent manner.

 

4.2.2                     Brand Strategy.  Veracyte shall provide marketing and brand strategy for the Test in accordance with the Annual Commercial Plan and any directions or instructions provided from time to time by the Steering Committee, and shall reasonably consider any input provided by Genzyme.

 

21

 

4.3                               Education and Training.  Unless otherwise agreed upon by the Steering Committee, Veracyte shall educate and train Genzyme’s and, to the extent its Affiliates employ sales and marketing personnel used to promote, market, detail and sell the Test, such Affiliates’ training personnel in order that such training personnel may provide general training to Genzyme’s and its Affiliates’ sales and marketing representatives regarding the Test, it being understood that (i) Veracyte will provide Genzyme, free of charge, with reasonable quantities of training materials which have been created and developed by Veracyte relating to the Test, and (ii) Genzyme and its Affiliates shall not permit any of their respective sales and marketing personnel to promote, market, detail and sell the Test unless such sales and marketing personnel have been trained by Genzyme’s or its Affiliates’ training personnel trained by Veracyte (or Genzyme as provided below in this Section 4.3).  Genzyme and its Affiliates referenced above shall make their respective training personnel available for such training and participate in conducting such training.  As between the parties hereto and except as expressly provided otherwise elsewhere in this Agreement, Veracyte shall exclusively own all right, title and interest in training materials developed under this Agreement except for any content specifically related to Thyrogen or other Genzyme products and any Genzyme Trademarks (which shall be exclusively owned by Genzyme).  Genzyme may translate such training materials into the local language used in any Country and may make copies of such training materials for use in its internal training programs.  The parties shall mutually decide on the times and locations of the training of such training personnel, and, unless the parties agree otherwise in writing, Genzyme and Veracyte will be responsible for the costs of transporting, housing and maintaining their respective personnel conducting or receiving such training.  As additional members are added to Genzyme’s or its Affiliates’ training personnel responsible for training the sales forces responsible for marketing and promoting the Test, training will be provided to such newly added members by Genzyme using the training materials initially developed by Veracyte.

 

4.4                               Recalls.

 

4.4.1                     Each party shall promptly (but in any case, not later than forty-eight (48) hours) notify the other party in writing of any order, request or directive of a court or other governmental agency or Regulatory Authority to recall or withdraw the Test.  Veracyte shall be responsible and have sole authority for handling all inquiries, Complaints, or recalls of the Test at its sole cost and expense, keeping Genzyme fully informed as to its plans and actions related to any such recall.  If requested by Veracyte, Genzyme shall fully cooperate with a Test recall in the Territory and follow all instructions given by Veracyte in that regard.

 

If a party (a) is contacted by any other Regulatory Authority or governmental agency for any purpose pertaining specifically to this Agreement or to the Test or (b) becomes aware of an impending inspection or audit of the facilities or operations involved with the Test, such party shall immediately notify the other party in writing.  Genzyme agrees that it shall not respond to any such agency making an inquiry of it until and only as directed by Veracyte; provided, however, that the foregoing shall not be construed to prevent Genzyme in any way from

 

22

 

complying with any governmental agency or Regulatory Authority or applicable laws, rules or regulations.

 

4.4.2                     In the event that Veracyte considers initiating a voluntarily recall of the Test in any Country, such recall shall be at Veracyte’s expense, and Veracyte shall promptly inform Genzyme of such deliberations (including the contributing facts and circumstances leading up to such deliberations) and of its final determination, and keep Genzyme fully informed as to its plans and actions related to any such voluntary recall.

 

4.5                               Test Shortage and/or Supply Interruption.

 

4.5.1                     If Veracyte is unable to meet the volume of requisitions for the Test in any Country, Veracyte shall allocate supply of the Test among all Countries where the Test is sold in a fair and equitable manner as reasonably determined by Veracyte.  If any such allocation would lead to a material shortage of the Test in a particular Country, the implications thereof in terms of the promotional, marketing and detailing efforts of each party under this Agreement shall be discussed and decided by the Steering Committee as soon as practicable.

 

4.5.2                     In case of a long term inability of Veracyte to provide the Test in any Country, each party is entitled, pending a decision by the Steering Committee in accordance with Section 4.5.1 above, to unilaterally decrease its promotional, marketing and detailing efforts under this Agreement in that particular Country in a way that is fair and proportionate to the shortage or interruption, given the nature and the anticipated duration of the shortage or interruption.

 

4.6                               Communications.  Genzyme may from time to time develop and issue press releases pertaining to this Agreement and/or the Test.  Such press releases shall contain both parties’ names and logos and shall not be published in any manner or form without prior written approval by Veracyte, such approval not to be unreasonably withheld, conditioned or delayed, and in accordance with Section 12.7 hereof.  Veracyte may from time to time develop and issue press releases pertaining to this Agreement.  Such press releases shall contain both parties’ names and logos and shall not be published in any manner or form without prior written approval by Genzyme, such approval not to be unreasonably withheld, conditioned or delayed, and in accordance with Section 12.7 hereof.  Notwithstanding the foregoing, Veracyte may from time to time issue press releases pertaining to the Test or any Improvements, including research studies, publications, announcements or other materials.  Such Test related press releases may be done only with Veracyte’s name and logo and will not require the prior written approval by Genzyme.  Veracyte will, however, provide Genzyme with a copy of such press release prior to its issuance and will consider any comments provided in a timely fashion by Genzyme.

 

4.7                               Periodic Reporting.  Veracyte shall provide Genzyme with aggregate data regarding (without limitation) Test orders, Test status, Test volume and any other information reasonably requested by Genzyme on a monthly or calendar quarterly basis (depending

 

23

 

on the type of information required) as mutually agreed upon by the parties.  Any such data shall be treated as Confidential Information of Veracyte and shall be maintained by Genzyme in accordance with Section 7 hereof.  Notwithstanding the foregoing or any other provision in this Agreement, in no case shall Veracyte be required to provide or disclose to Genzyme any information that would violate any applicable laws and regulations.

 

4.8                               Complaint Reporting; Result Errors and CAPAs; Pharmacovigilance.

 

4.8.1                     Veracyte shall be responsible for evaluating and reporting any Complaints to Regulatory Authorities or other entities in the Territories as required by applicable laws and regulations.  In addition, Veracyte shall provide Genzyme with any and all Complaints and other related information obtained by Veracyte regarding the Test as well as all correspondence to and from Regulatory Authorities or other entities related thereto.

 

4.8.2                     Veracyte shall provide Genzyme with (i) reports regarding all patient result errors, (ii) all Corrective Actions/Preventative Actions (“CAPAs”) that relate to matters that would reasonably be deemed material to the normal commercialization of the Test and (iii) copies of all similar reports submitted to Regulatory Authorities or other entities as well as all correspondence to and from Regulatory Authorities or other entities related thereto.  Notwithstanding the foregoing or anything to the contrary, Veracyte will not be required to provide Genzyme with any information or data that would violate any applicable rule or regulation including HIPAA or any other rule regarding the confidentiality or non-disclosure of patient information or data.

 

4.8.3                     Veracyte shall report Safety Information (as defined in Exhibit E) pertaining to the Subject Products in accordance with the procedures described in Exhibit E.  The procedures described in Exhibit E do not restrict Genzyme’s ability to take such action as it deems appropriate or required under applicable law or regulations.

 

4.9                               Regulatory Matters.

 

4.9.1                     Marketing Authorization.

 

(a)                                 Comprehensive Services.  Genzyme shall be responsible and have sole authority for seeking, obtaining and maintaining Marketing Authorization for the Test in each Country in the Comprehensive Services Territory in accordance with the then current Annual Commercial Plan.  Such activities shall be at Genzyme’s sole cost and expense.  Veracyte shall provide such assistance as may be reasonably required for the purpose of seeking, obtaining and maintaining Marketing Authorization for the Test in any Country in the Comprehensive Services Territory, subject to the availability of such resources.

 

24

 

(b)                                 Dedicated Promotion Only.  Unless otherwise specified in Exhibit A (Country Specific Terms), Veracyte shall be responsible and have sole authority for seeking, obtaining and maintaining Marketing Authorization for the Test in each Country in the Dedicated Promotion Only Territory in accordance with the then current Annual Commercial Plan.  Unless otherwise specified in Exhibit A (Country Specific Terms), such activities shall be at Veracyte’s sole cost and expense.  Genzyme shall provide such assistance as may be reasonably required for the purpose of seeking, obtaining and maintaining Marketing Authorization for the Test in any Country in the Dedicated Promotion Only Territory, subject to the availability of such resources and at Veracyte’s expense.

 

4.9.2                     Reimbursement.

 

(a)                                 Comprehensive Services.  Genzyme shall be responsible and have sole authority for seeking, obtaining and maintaining pricing approval and reimbursement for the Test in each Country in the Comprehensive Services Territory in accordance with the then current Annual Commercial Plan.  Such activities shall be at Genzyme’s sole cost and expense.  Veracyte shall provide such assistance as may be reasonably required for the purpose of seeking, obtaining and maintaining pricing approval and reimbursement in any Country in the Comprehensive Services Territory, subject to the availability of such resources.

 

(b)                                 Dedicated Promotion Only.  Veracyte shall be responsible and have sole authority for seeking, obtaining and maintaining pricing approval and reimbursement for the Test in each Country in the Dedicated Promotion Only Territory in accordance with the then current Annual Commercial Plan.  Such activities shall be at Veracyte’s sole cost and expense.  Genzyme shall provide such assistance as may be reasonably required for the purpose of seeking, obtaining and maintaining pricing approval and reimbursement in any Country in the Dedicated Promotion Only Territory, subject to the availability of such resources and at Veracyte’s expense.

 

4.9.3                     Clinical Studies.  For clinical trials as reasonably determined by the Steering Committee, Veracyte shall plan and execute, at its sole expense, all clinical trials of the Test necessary to obtain or maintain the Marketing Authorization of the Test in any Country that is a Dedicated Promotion Only Territory, and Genzyme shall plan and execute, at its sole expense, all clinical trials of the Test necessary to obtain or maintain the Marketing Authorization of the Test in any Country that is a Comprehensive Services Territory

 

4.10                        Performance by Veracyte Affiliates and Subcontractors.  Notwithstanding anything to the contrary contained in this Agreement, any Veracyte obligation hereunder may be assumed and performed by one or more of its Affiliates, and Veracyte may, at its election, delegate to any one or more of its Affiliates any duty or responsibility set forth in this Agreement; provided, however, that Veracyte shall remain responsible for any and

 

25

 

all acts and omissions by such Affiliate(s) to the same extent as if such were performed, taken or made by Veracyte.  Furthermore, it is anticipated that Veracyte may perform certain of its obligations hereunder through third party laboratories and other subcontractors.  In such event, as between the parties, Veracyte shall remain responsible for any and all acts and omissions by such third parties to the same extent as if such were performed, taken or made by Veracyte.

 

4.11                        Billing and Collections.

 

4.11.1              Comprehensive Services.  Expect as otherwise provided in Exhibit A, unless otherwise required by applicable laws and regulations, Genzyme and its Affiliates shall book all sales of the Test in the Comprehensive Services Territory and shall be responsible for the billing, invoicing, claims submissions, and collection of receivables and amounts due resulting from the sales of the Test in the Comprehensive Services Territory (collectively, “CS Collection Activities”), and such activities shall be at Genzyme’s cost and expense.  Genzyme and its Affiliates shall use Commercially Reasonable Efforts in performing the CS Collection Activities.  Veracyte shall provide reasonable support and assistance to Genzyme as requested by Genzyme (including if Genzyme and its Affiliates are prohibited from performing CS Collection Activities in a particular Country under applicable laws and regulations) at Genzyme’s cost and expense, subject to the availability of such resources.

 

4.11.2              Dedicated Promotion Only.  Unless otherwise required by applicable laws and regulations, Veracyte and its Affiliates shall book all sales of the Test in the Dedicated Promotion Only Territory and shall be responsible for the billing, invoicing, claims submissions, and collection of receivables and amounts due resulting from the sales of the Test in the Dedicated Promotion Only Territory (collectively, “DPO Collection Activities”), and such activities shall be at Veracyte’s cost and expense.  Veracyte and its Affiliates shall use Commercially Reasonable Efforts in performing the DPO Collection Activities.  Genzyme shall provide reasonable support and assistance to Veracyte as requested by Veracyte (including if Veracyte and its Affiliates are prohibited from performing DPO Collection Activities in a particular Country under applicable laws and regulations) at Veracyte’s cost and expense, subject to the availability of such resources.

 

4.12                        Veracyte Right to Co-Promote.  Veracyte shall have the right, but not the obligation, to market, promote, and detail the Test in the Dedicated Promotion Only Territory with Genzyme.  If Veracyte chooses to exercise this right, Veracyte shall deliver written notice of such election to Genzyme.

 

26

 

4.13                        Test Collection Kit Supply and Distribution.  Veracyte shall be responsible for managing Collection Kit supply, inventory, tracking and distribution, shall be responsible for the costs associated with the supply and distribution of Collection Kits and shall use its Commercially Reasonable Efforts in such activities.  Genzyme will assist Veracyte to achieve economies of scale within a given Country (e.g., use of Genzyme or Sanofi’s distribution facilities) at Veracyte’s expense.

 

SECTION 5 — MANAGEMENT AND GOVERNANCE

 

5.1                               Steering Committee.  The sales and marketing program for the Test in the Territories will be managed by a steering committee having equal representation of the parties (the “Steering Committee”), which Steering Committee may be the same as the “Steering Committee” (as defined in the U.S. Co-Promotion Agreement) managing the U.S. Co-Promotion Agreement.  The Steering Committee will include three (3) members from each party and will meet in-person at least quarterly with at least one (1) meeting per year being conducted in person while more frequent meetings or teleconferences will be held anytime they are needed and requested by the Steering Committee’s members of either party.  If an in-person meeting is impracticable, meetings may be held by videoconference or teleconference.  When meetings are held in person, individual members of the Steering Committee may nonetheless participate by videoconference or teleconference.  If unable to attend in person or by videoconference or teleconference, an individual member of the Steering Committee may grant a proxy to another individual member of the Steering Committee in order to act on his or her behalf on any matter to be acted upon at any meeting of the Steering Committee.  Other representatives of the parties may attend Steering Committee meetings as non-voting participants.  At least one week prior to any meeting of the Steering Committee, the parties shall agree upon a proposed agenda of the matters to be discussed at such meeting.  The parties shall agree, at the first meeting of the Steering Committee, upon procedures for maintaining meeting minutes.  The Steering Committee may take action on a matter at a meeting only if a quorum exists with respect to that matter.  The attendance of at least two (2) members of the Steering Committee of each party at a meeting shall constitute a quorum for the transaction of business.  Each member of the Steering Committee shall be entitled to cast one (1) vote, either in person or by proxy, on any matter to be acted upon at any meeting of the Steering Committee.  All decisions made by the Steering Committee shall require a majority vote by the members of the Steering Committee, either in person or by proxy.  Any action required or permitted to be taken at any meeting of the Steering Committee may be taken without a meeting if the action is taken by all members of the Steering Committee.  Such action must be evidenced by one or more written consents describing the action taken and signed by each member of the Steering Committee.  In the event the Steering Committee is unable to achieve a majority vote on any issue, then the dispute resolution process set forth in Section 5.3 hereof will be followed with respect to such issue.

 

5.2                               Responsibilities.  The responsibilities of the Steering Committee (which may be delegated to sub-groups by approval of the Steering Committee) will include, without limitation:

 

27

 

5.2.1                     approving the Annual Commercial Plan (including the budget therein); provided, however, the Annual Commercial Plan approved by the Steering Committee must conform with the requirements of Section 3.2;

 

5.2.2                     determining the types and forms of Ad/Prom Materials to be created (e.g., printed materials, television media, digital media such as website content or e-marketing) and reviewing and approving all Ad/Prom Materials for the Test and sales force training materials before first use in the Territories; provided, however, that the Steering Committee may delegate review and approval of the Ad/Prom Materials to Genzyme’s and Veracyte’s respective marketing review committees, and if the marketing review committees of both parties separately approve the Ad/Prom Materials, the Steering Committee shall be deemed to have approved such Ad/Prom Materials;

 

5.2.3                     approving Test launch order and timing for Countries in the Territories;

 

5.2.4                     planning, monitoring and evaluating the overall sales and marketing program for the Test in each Country and ensuring the program is compliant with best practices in each Country and all applicable laws and regulations;

 

5.2.5                     implementing the marketing and promotion strategy for the Test in each Country in order to market, promote and detail the Test in the most effective and efficient fashion; and

 

5.2.6                     any other activities specifically provided for in this Agreement.

 

The members of the Steering Committee from each party shall have the right to comment upon and make recommendations to the members of the other party regarding the other party’s activities under this Agreement, which recommendations the other party shall be reasonably considered.

 

5.3                               Steering Committee Dispute Resolution.

 

5.3.1                     Should the Steering Committee be unable to reach a unanimous decision on any matter after ten (10) business days following the date on which the relevant meeting or teleconference has been held, the decision will be escalated to senior management representatives of the parties, who will have an additional ten (10) business days to reach a mutually agreeable decision.  If the senior management representatives are unable to resolve such a dispute or issue within such ten (10) day period after being requested to resolve such dispute or issue, the dispute or issue shall be referred to the Chief Executive Officers of Veracyte and Genzyme, or their designees, for attempted good faith resolution by negotiation within thirty (30) calendar days after such referral.  If the Chief Executive Officers of the parties, or their designees, are unable to resolve such dispute or issue, then the matter may be referred to mediation as set forth in Section 5.3.2 hereof.

 

5.3.2                     If a dispute cannot be resolved pursuant to Section 5.3.1 hereof, the parties shall in good faith attempt to resolve such dispute by non-binding mediation

 

28

 

administered by JAMS End Dispute in accordance with its commercial mediation rules.  The mediation will be conducted by a single mediator appointed by agreement of the parties or, failing such agreement, by JAMS End Dispute in accordance with its commercial mediation rules.  Unless otherwise mutually agreed by the parties, the mediation proceedings will be conducted in Chicago, Illinois.  The parties shall share equally the cost of the mediation including, without limitation, filing fees, hearing fees and the cost of the mediator(s).  Each party will bear its own attorneys’ fees and associated costs and expenses.  If the dispute has not been resolved by the means provided herein within one hundred eighty (180) calendar days of the initiation of such procedure, either party shall have the right to file a lawsuit to resolve the dispute; provided, however, if Veracyte files such lawsuit, it must be filed in the courts of Boston, Massachusetts and if Genzyme files such lawsuit, it must be filed in the courts in San Francisco, California.

 

5.4                               Coordination of Calls.  Efforts will be made by the Steering Committee to coordinate the Calls by the Veracyte sales forces, if any and as applicable, with the Calls by the Genzyme sales forces to ensure the most effective coverage of the target audiences and to minimize duplication of efforts to the extent practicable.

 

5.5                               Participation Cost.  Each party shall bear its own costs associated with its participation in the Steering Committee and its activities performed under this Agreement, except as otherwise set forth herein.

 

SECTION 6 - FINANCIAL TERMS

 

6.1                               Promotion Fees.

 

6.1.1                     Comprehensive Services.  Genzyme shall book all sales of the Test in the Comprehensive Services Territory.  Subject to the provisions of and during the Term of this Agreement, as compensation for its activities and obligations under this Agreement in the Comprehensive Services Territory and for the grant of rights under Section 2.1.1 in the Comprehensive Services Territory, Genzyme shall pay Veracyte a royalty calculated on a Country-by-Country basis (the “CS Royalty”) equal to the Country Payment Rate multiplied by the Net Revenue received by Genzyme or its Affiliates for sales of the Test in each Country in the Comprehensive Services Territory, or a fee per test as set forth on any exhibit attached hereto as Country Specific Terms.  Such CS Royalty or fees, as the case may be, shall be due on a quarterly basis as set forth in Section 6.3 below.

 

6.1.2                     Dedicated Promotion Only.  Veracyte shall book all sales of the Test in the Dedicated Promotion Only Territory.  Subject to the provisions of and during the Term of this Agreement, as compensation for its activities and obligations under this Agreement in the Dedicated Promotion Only Territory, Veracyte shall pay Genzyme a fee calculated on a Country-by-Country basis (the “DPO Promotion Fees”) equal to the Country Payment Rate multiplied by the Net Revenue received by Veracyte or its Affiliates for sales of the Test in each Country in the

 

29

 

Dedicated Promotion Only Territory.  Such DPO Promotion Fees shall be due on a quarterly basis as set forth in Section 6.3 below.

 

6.2                               Quarterly Net Revenue Report.

 

6.2.1                     Within thirty (30) calendar days after the close of each calendar quarter that occurs during the Term of this Agreement and within thirty (30) calendar days after the end of the Term, Genzyme shall submit to Veracyte a statement (the “Genzyme Quarterly Net Revenue Report”) showing, with respect to each Country in the Comprehensive Services Territory:

 

(a)                                 Net Revenues, with breakouts of revenues attributable to cytopathology versus molecular testing services and regional breakouts;

 

(b)                                 the amount billed and the amount reimbursed for each claim, and the payor associated with each such claim; and

 

(c)                                  the calculation of the CS Royalty due to Veracyte pursuant to Section 6.1; or

 

(d)                                 the number of Tests sold during such period in the case of a fee for Test model, if such model is part of an exhibit attached hereto as a Country Specific Terms sheet.

 

Any such Genzyme Quarterly Net Revenue Report shall be treated as Confidential Information of Genzyme in accordance with Section 7 hereof.

 

6.2.2                     Within thirty (30) calendar days after the close of each calendar quarter that occurs during the Term of this Agreement and within thirty (30) calendar days after the end of the Term, Veracyte shall submit to Genzyme a (the “Veracyte Quarterly Net Revenue Report”) showing, with respect to each Country in the Dedicated Promotion Only Territory:

 

(a)                                 Net Revenues, with breakouts of revenues attributable to cytopathology versus molecular testing services, regional breakouts;

 

(b)                                 the amount billed and the amount reimbursed for each claim, and the payor associated with each such claim; and

 

(c)                                  the calculation of the DPO Promotion Fees or LC Promotion Fees, as applicable, due to Genzyme pursuant to Section 6.1.

 

Any such Veracyte Quarterly Net Revenue Report shall be treated as Confidential Information of Veracyte in accordance with Section 7 hereof.

 

6.3                               Invoicing and Payment.  Invoicing shall take place on a quarterly basis.  Each invoice shall be based on the data contained in the Genzyme Quarterly Net Revenue Reports received by Veracyte and the Veracyte Quarterly Net Revenue Reports received by

 

30

 

Genzyme in accordance with Section 6.2 above and payment shall be due not more than thirty (30) calendar days from the date of invoice and may be made in the form of a wire transfer.  With respect to invoices for assistance and support provided by one party to the other party at such other party’s expense pursuant to the terms and conditions of this Agreement, payment shall be due within thirty (30) calendar days after receipt of a reasonably detailed invoice for such assistance and support.

 

6.4                               Annual Reconciliation.

 

6.4.1                     The Genzyme Quarterly Net Revenue Report for the fourth quarter of each calendar year shall contain an annual reconciliation indicating the difference, if any, between the annual CS Royalty (calculated on the basis of the Net Revenue reported for the entire calendar year) and the sum of all quarterly CS Royalties (calculated on the basis of the Net Revenue reported per calendar quarter).  In case of a difference, the relevant amount shall be settled in Veracyte’s invoice for the fourth quarter of the relevant calendar year.

 

6.4.2                     The Veracyte Quarterly Net Revenue Report for the fourth quarter of each calendar year shall contain an annual reconciliation indicating the difference, if any, between the annual DPO Promotion Fees and LC Promotion Fees (calculated on the basis of the Net Revenue reported for the entire calendar year) and the sum of all quarterly DPO Promotion Fees and LC Promotion Fees (calculated on the basis of the Net Revenue reported per calendar quarter).  In case of a difference, the relevant amount shall be settled in Genzyme’s invoice for the fourth quarter of the relevant calendar year.

 

SECTION 7 - CONFIDENTIALITY

 

7.1                               Non-Disclosure and Non-Use of Confidential Information.  All Confidential Information shall remain the exclusive property of the Disclosing Party during the Term of this Agreement and thereafter.  The Receiving Party shall disclose such Confidential Information only to those of its (and its Affiliates’) agents, advisors, consultants and employees to whom it is necessary in order to carry out their duties hereunder as limited by the terms and conditions of this Agreement.  During the Term of this Agreement and thereafter, all of the Disclosing Party’s Confidential Information shall be maintained in strict confidence by the Receiving Party’s agents and employees, and shall not be used by the Receiving Party for any purpose other than in connection with the Receiving Party’s performance of its duties under this Agreement.  The Receiving Party shall, at its expense and at the Receiving Party’s option, either return or destroy (and certify such destruction to the Disclosing Party in a written instrument signed by an officer of the Receiving Party) all Confidential Information of the Disclosing Party within sixty (60) days after the expiration or termination of this Agreement; provided, however, that the Receiving Party may retain one (1) copy of the Confidential Information of the Disclosing Party for archival purposes.

 

31

 

7.2                               Exceptions to Confidentiality Obligations.  The limitations on use and disclosure set forth in Section 7.1 hereof shall not apply to information which the Receiving Party can demonstrate:

 

7.2.1                     was in the public domain at the time of disclosure without breach of this Agreement by the Receiving Party;

 

7.2.2                     was known to or contained in the records of the Receiving Party from a source other than the Disclosing Party at the time of disclosure and can be so demonstrated by written records of the Receiving Party;

 

7.2.3                     was independently developed by the Receiving Party without use of, reference to or reliance upon the Disclosing Party’s Confidential Information and can be so demonstrated by written records of the Receiving Party; or

 

7.2.4                     became known or was disclosed to the Receiving Party without restriction on further disclosure from a third party source having the right to make such disclosure.

 

7.3                               Disclosure Pursuant to Legal Obligation.  Notwithstanding any other provision of this Agreement, disclosure of any portion of the Disclosing Party’s Confidential Information shall not be prohibited to the extent that it is required to (i) comply with applicable law, order or regulation of a governmental agency or a court of competent jurisdiction, (ii) to comply with any governmental agency for purposes of obtaining Marketing Authorization for the Test, or (iii) as necessary to establish the rights of either party under this Agreement, provided in either case that the Receiving Party shall (A) provide to the Disclosing Party prompt written notice of the existence, terms and circumstances of such required disclosure with at least sufficient detail to enable such Disclosing Party to seek a protective order or otherwise prevent or limit the extent of such disclosure, (B) consult with the Disclosing Party on the advisability of taking legally available steps to resist or narrow such disclosure, (C) take all reasonable and lawful actions to obtain confidential treatment for such disclosure and (D) thereafter disclose only such Confidential Information as is reasonably necessary under the circumstances.  Each of the parties agrees that the foregoing exceptions are to be narrowly construed and that its obligations (and those of its representatives) under this Section 7 are released solely with respect to those specific portions of the Disclosing Party’s Confidential Information that fall within the foregoing exceptions and not with respect to related portions.

 

7.4                               Disclosure to Prospective Investors.  Notwithstanding any other provision of this Agreement, Veracyte may disclose Confidential Information, including the terms of this Agreement, to current and prospective investors in Veracyte, provided any such recipients are bound by confidentiality and non-use provisions no less restrictive than those contained in this Section 7.

 

SECTION 8 - INFRINGEMENT AND LITIGATION

 

8.1                               Infringement.  If either party reasonably believes or learns that a third party is infringing or misappropriating Veracyte Intellectual Property in a Country in which the Test is

 

32

 

being made, used, sold, offered for sale and/or imported, that party shall give the other party prompt written notice of its belief and documentation supporting its belief.  The parties shall use good faith efforts to coordinate and cooperate in any action, negotiation, or settlement of the alleged infringement.

 

8.2                               Litigation.  If Genzyme reasonably believes that there is infringement of any Veracyte Owned Intellectual Property by a third party and Genzyme submits documentary support of such activity to Veracyte, then Veracyte, acting at its own expense and for its own account, shall have the right, but not the obligation, to enforce the Veracyte Owned Intellectual Property against such infringers, including bringing any legal action for infringement and defending against any counter claims in such action.  Genzyme shall provide to Veracyte, at Veracyte’s expense, such assistance and cooperation as may reasonably be requested by Veracyte or required in Veracyte’s action against such third party.  If Veracyte does not initiate action to terminate any infringement of the Veracyte Owned Intellectual Property within six (6) months after receiving such documentary support, or earlier notifies Genzyme in writing that it does not intend to bring such action, then Genzyme, upon receipt of consent from Veracyte, which consent shall not unreasonably withheld, conditioned or delayed, may bring such suit regarding infringement or misappropriation of such Veracyte Owned Intellectual Property in a Country, acting in its own name or in the name of Veracyte, but for Genzyme’s own account and at Genzyme’s own expense, any recovery to be for its own account.  Veracyte hereby agrees to cooperate and be joined as a nominal party plaintiff to such suit and shall render, at Genzyme’s expense, all reasonable assistance and cooperation as may be reasonably necessary in such a suit.  Notwithstanding the foregoing, Genzyme may not enter into any settlement, consent judgment or other voluntary final disposition of such action which adversely affects any Veracyte Owned Intellectual Property without the prior written consent of Veracyte, which will not be unreasonably withheld, conditioned or delayed.  Each party instituting any such infringement actions shall, subject the foregoing, have the right to make all decisions regarding the prosecution of any such action and shall keep the other party reasonably informed as to the status of such action.  It is understood and agreed that the provisions of this Section 8.2 shall only apply to Veracyte Owned Intellectual Property that Veracyte or its Affiliates have the right to enforce (by virtue of ownership, license terms, or otherwise).

 

8.3                               Licenses.  If a third party license is required in order that the activities required pursuant to this Agreement do not infringe a third party’s Intellectual Property Rights, then Veracyte, at Veracyte’s expense and acting in its own name, shall negotiate with such third party and use Commercially Reasonable Efforts to obtain such a license.  Genzyme shall give to Veracyte, at Veracyte’s sole expense, such assistance as may reasonably be requested by Veracyte in connection with Veracyte’s negotiation with such third party, subject to the availability of such resources.

 

8.4                               Notification.  In the event that either party receives notification of any alleged or actual infringement from a third party, that party shall provide the other party with a copy of such notification within five (5) business days after its receipt of the notification.

 

33

 

SECTION 9 - REPRESENTATIONS AND WARRANTIES

 

9.1                               Veracyte represents and warrants to Genzyme that as of the Effective Date:

 

9.1.1                     Veracyte and its Affiliates exclusively owns or controls the Veracyte Owned Intellectual Property and has the right to license or sublicense to Genzyme and its Affiliates all Veracyte Intellectual Property licensed hereunder, that such rights to such Veracyte Intellectual Property have been validly granted to Genzyme and its Affiliates, and that the granting of such rights to Genzyme and its Affiliates does not require the consent of a third party in accordance with the terms of this Agreement;

 

9.1.2                     (a) there are no claims, judgments or settlements against or owed by Veracyte or its Affiliates, or to the best of its knowledge, any pending or threatened claims or litigation relating to the Veracyte Owned Intellectual Property, the Test or the Ad/Prom Material used by Veracyte prior to the Effective Date; (b) to the best of its knowledge, there are no claims, judgments or settlements against or owed by Veracyte or its Affiliates relating to any other Veracyte Intellectual Property and (c) to the best of its knowledge, there are no pending or threatened claims or litigation relating to other Veracyte Intellectual Property that to the knowledge of Veracyte would have a material adverse effect on the Test, Veracyte, or the ability of the parties to perform under of this Agreement;

 

9.1.3                     to the best of Veracyte’s knowledge, there are no third party patent, patent application or other third party Intellectual Property Rights that would be infringed by making, using, or selling the Test;

 

9.1.4                     to the best of Veracyte’s knowledge, (a) there is no infringement or misappropriation by a third party of the Veracyte Owned Intellectual Property and/or the Test and (b) there is no misappropriation by a third party of other Veracyte Intellectual Property that to the knowledge of Veracyte would have a material adverse effect on the Test, Veracyte, or the ability of the parties to perform under of this Agreement;

 

9.1.5                     Veracyte has the full right, power and authority and legal capacity to enter into this Agreement and to grant the rights and licenses granted under Section 2 hereof and the execution, delivery and performance of this Agreement by Veracyte does not conflict with, or constitute a breach of or under, any order, judgment, agreement or instrument to which Veracyte is a party;

 

9.1.6                     Veracyte is a duly organized and validly existing corporation under the laws of its jurisdiction of incorporation;

 

9.1.7                     Veracyte (and any third party laboratories and other subcontractors used by Veracyte) has all necessary licenses, permits and certifications under all applicable laws, regulations, codes, and standards determined by any governmental authority or Regulatory Authority (including without limitation CLIA and similar state laws, as well as all generally applicable industry standards

 

34

 

whether the same are regional, national or international), to use, make and commercialize Afirma in the Territories;

 

9.1.8                     neither Veracyte nor any of its Affiliates has granted any right or license to any third party relating to the Veracyte Owned Intellectual Property and/or the Test that would conflict with the rights granted to Genzyme and its Affiliates under this Agreement; and

 

9.1.9                     Exhibit C hereto includes all patents or patent applications of Veracyte that are included in the Veracyte Owned Intellectual Property that are in existence or filed as of the Effective Date (other than foreign counterparts).

 

9.2                               No Conflicting Obligations.  Each party represents and warrants that the execution of this Agreement and the performance of its obligations hereunder will not conflict with, result in the breach of, or constitute a default under, any agreement to which it, its officers, directors, agents or employees are parties, or by which it, its officers, directors, agents or employees are or may be bound.

 

9.3                               Compliance with Applicable Laws.  Each party represents and warrants that in the performance of its obligations under this Agreement it shall comply with all applicable laws, regulations, codes, and standards determined by any governmental authority or Regulatory Authority, as well as all generally applicable industry standards whether the same are regional, national or international.

 

9.4                               Ad/Prom Materials and Training Materials.  Veracyte hereby represents and warrants to Genzyme that all Ad/Prom Materials and training materials used by Veracyte as of the Effective Date in connection with the Test comply, and all Ad/Prom Materials and training materials to be created and developed by Veracyte pursuant to Sections 3.5.1 and 4.3 hereof will comply, with all applicable laws, regulations, codes and standards determined by any governmental authority or Regulatory Authority, as well as all generally applicable industry standards whether the same are regional, national or international.

 

9.5                               FCPA.

 

9.5.1                     Each party represents and warrants that it:

 

(a)                                 is aware of the terms of the U.S. Foreign Corrupt Practices Act (“FCPA”); and

 

(b)                                 is not an officer or agent of a governmental authority or regulatory authority within the Territories.

 

9.5.2                     In performing its obligations under this Agreement, each party shall refrain from any violation of the FCPA.  Without limiting the generality of the foregoing, neither party shall pay money or provide any other thing of value to any foreign officials in violation of the FCPA or any other statute or regulation in a Territory.

 

35

 

9.6                               Performance Standards.

 

9.6.1                     Each party represents and warrants that all activities and obligations performed under this Agreement will be performed by it and its Affiliates (i) in a professional and workmanlike manner, (ii) by appropriately qualified individuals who are licensed in accordance with applicable laws and regulations in the country in which they are performed, (iii) at an appropriately qualified and licensed laboratory facility, and (iv) in accordance with the standard of care and best industry practices in the country in which they are performed.

 

9.6.2                     Veracyte represents and warrants that neither Veracyte nor its Affiliates (to the extent its Affiliates are performing services related to the Test), nor any of their respective employees or agents performing services related to Test in connection with this Agreement, has been: (i) convicted of an offense related to any federal or state health care program; (ii) debarred under the Federal Food, Drug and Cosmetic Act; or (iii) excluded or is otherwise ineligible for federal or state health care program participation.  No convicted, debarred, excluded or ineligible person will in the future be employed by Veracyte or its Affiliates, to their knowledge, in connection with any of its obligations under this Agreement.  If Veracyte becomes aware that Veracyte or its Affiliates performing services related to the Test or any person employed or contracted by Veracyte or its Affiliates in connection with this Agreement has become or is in the process of being convicted, debarred, excluded or otherwise rendered ineligible for federal or state health care program participation, Veracyte shall so notify Genzyme in writing.

 

9.6.3                     Genzyme represents and warrants that neither Genzyme nor its Affiliates (to the extent its Affiliates either employ sales and marketing personnel used to promote, market or detail any Thyrogen or the Test or otherwise perform services hereunder), nor any employee or agent of Genzyme or such Affiliates marketing, promoting, or detailing the Test in connection with this Agreement, has been: (i) convicted of an offense related to any federal or state health care program; (ii) debarred under the Federal Food, Drug and Cosmetic Act; or (iii) excluded or is otherwise ineligible for federal or state health care program participation.  No convicted, debarred, excluded or ineligible person will in the future be employed by Genzyme or its Affiliates, to their knowledge, in connection with any of its obligations under this Agreement.  If Genzyme becomes aware that Genzyme its Affiliates mentioned above or any person employed or contracted by Genzyme or such Affiliates in connection with this Agreement has become or is in the process of being convicted, debarred, excluded or otherwise rendered ineligible for federal or state health care program participation, Genzyme shall so notify Veracyte in writing.

 

9.7                               Genzyme represents and warrants to Veracyte that as of the Effective Date:

 

9.7.1                     Genzyme has the full right, power and authority and legal capacity to enter into this Agreement;

 

36

 

9.7.2                     the execution, delivery and performance of this Agreement by Genzyme does not conflict with, or constitute a breach of or under, any order, judgment, agreement or instrument to which Genzyme is a party; and

 

9.7.3                     Genzyme or its Affiliates directly employs a direct sales force in each Country, with respect to Thyrogen such sales force operates with all necessary licenses, permits and certifications under all applicable laws, regulations, codes, and standards determined by any applicable governmental authority or Regulatory Authority as of the Effective Date.

 

9.8                               EXCEPT AS EXPRESSLY STATED IN THIS SECTION 9, ALL OTHER WARRANTIES, CONDITIONS AND REPRESENTATIONS, EXPRESS OR IMPLIED, STATUTORY OR OTHERWISE, INCLUDING A WARRANTY AS TO THE QUALITY OR FITNESS FOR ANY PARTICULAR PURPOSE OF THE TEST, ARE HEREBY EXCLUDED.

 

SECTION 10 - INDEMNIFICATION AND LIMITATION OF LIABILITY

 

10.1                        Indemnification by Veracyte.

 

10.1.1              Veracyte shall defend, indemnify and hold Genzyme, its Affiliates and their respective officers, directors and employees harmless from and against any liabilities, charges, costs, or expenses, including reasonable attorneys’ fees and settlement payments (collectively, “Liabilities”) that arise from any claim, lawsuit or other action by a third party resulting from (i) the promotion, marketing or detailing of the Test by Veracyte or its Affiliates, (ii) the safety or effectiveness of the Test and/or the research, development, manufacture, commercialization, distribution, promotion, marketing, detailing or importation of the Test by Veracyte or its Affiliates, (iii) performance of the Test including, without limitation, the reporting of test results to physicians or patients, (iv) a breach by Veracyte of its covenants or the terms and conditions of this Agreement or any negligence or misconduct of Veracyte or its Affiliates or their respective employees, agents or subcontractors, (v) the infringement or other violation of any third party trademarks with respect to the use by Genzyme of the Veracyte Trademarks in accordance with the terms and conditions of this Agreement, (vi) an inaccuracy of any of Veracyte’s representations and warranties under this Agreement, (vii) an actual or alleged infringement of a patent, trademark or other Intellectual Property Right of a third party, (viii) the non-conformance of Collection Kits supplied to Genzyme pursuant to this Agreement with Veracyte’s standard warranty or any other warranty that Genzyme may be unable to disclaim as a matter of local law or (ix) product liability claims arising out of Genzyme’s distribution of Collection Kits in the Comprehensive Services Territory.  The foregoing obligations shall not apply to the extent that such Liabilities result from any gross negligence or willful misconduct of Genzyme or its Affiliates.

 

10.1.2              Genzyme shall promptly notify Veracyte of any liability in respect of which Genzyme intends to claim such indemnification, and Veracyte shall assume and

 

37

 

have exclusive control over the defense thereof with counsel selected by Veracyte; provided, however, that Genzyme shall have the right to fully participate in any such action or proceeding and to retain its own counsel, at its own expense, if representation of Genzyme by the counsel retained by Veracyte would be inappropriate under applicable standards of professional conduct due to actual or potential differing interests between Genzyme and Veracyte or any other party represented by such counsel in such proceedings.  The failure to deliver notice to Veracyte within a reasonable time after the commencement of such action shall relieve Veracyte of its indemnification obligations hereunder only to the extent such failure is prejudicial to Veracyte’s ability to defend such action.

 

10.2                        Indemnification by Genzyme.

 

10.2.1              Genzyme shall defend, indemnify and hold Veracyte, its Affiliates and their respective officers, directors and employees harmless from and against any Liabilities that arise from any claim, lawsuit or other action by a third party resulting from (i) the promotion, marketing or detailing of the Test by Genzyme or its Affiliates, (ii) a breach by Genzyme of its covenants or the terms and conditions of this Agreement or any negligence or misconduct of Genzyme or its Affiliates or their respective employees, agents or subcontractors, (iii) an inaccuracy of any of Genzyme’s representations and warranties under this Agreement or (iv) the infringement or other violation of any third party trademarks with respect to the use by Veracyte of the Genzyme Trademarks in accordance with the terms and conditions of this Agreement.  The foregoing obligations shall not apply to the extent that such Liabilities result from the gross negligence or willful misconduct of Veracyte or its Affiliates.  For the avoidance of doubt, Genzyme will not indemnify Veracyte and its Affiliates for any Liabilities resulting from an actual or alleged infringement of a patent, trademark or other Intellectual Property Right of a third party related to making, using or processing the Test.

 

10.2.2              Veracyte shall promptly notify Genzyme of any liability in respect of which Veracyte intends to claim such indemnification, and Genzyme shall assume and have exclusive control over the defense thereof with counsel selected by Genzyme; provided, however, that Veracyte shall have the right to fully participate in any such action or proceeding and to retain its own counsel, at its own expense, if representation of Veracyte by the counsel retained by Genzyme would be inappropriate under applicable standards of professional conduct due to actual or potential differing interests between Veracyte and Genzyme or any other party represented by such counsel in such proceedings.  The failure to deliver notice to Genzyme within a reasonable time after the commencement of such action shall relieve Genzyme of its indemnification obligations hereunder only to the extent such failure is prejudicial to Genzyme’s ability to defend such action.

 

38

 

10.3                        Limitation of Liability.

 

10.3.1              Neither party shall be liable to the other party for any special, incidental, indirect or consequential damages including, but not limited to, loss of profit, loss of savings, loss of business, loss or contracts, whether arising from negligence, breach of contract or in any other way.

 

10.3.2              The limitations set forth in Section 10.3.1 shall not apply with respect to the liability of either party for death, material personal injury or property damage, which has been determined by a court of final adjudication to have been proximately caused by the gross negligence or willful misconduct of such party or its Affiliates.

 

10.4                        Insurance.

 

10.4.1              Each party possesses and will maintain commercially reasonable amounts of insurance from a reputable insurance carrier (or by means of self-insurance) sufficient to cover its risks under this Agreement.

 

10.4.2              For the avoidance of doubt, Veracyte is required to maintain an active insurance policy covering general commercial liability, contractual liability, personal and advertising injury, errors and omissions, and product liability claims, with limits of not less than $10,000,000 (ten million dollars) per occurrence and $10,000,000 (ten million dollars) aggregate.  Veracyte shall name Genzyme as an “additional insured” and provide Genzyme with a certificate of insurance promptly upon Genzyme’s request.

 

10.4.3              For the avoidance of doubt, Genzyme is required to maintain an active insurance policy covering general commercial liability, contractual liability, personal and advertising injury, errors and omissions, and product liability claims, with limits of not less than $10,000,000 (ten million dollars) per occurrence and $10,000,000 (ten million dollars) aggregate.  Genzyme shall name Veracyte as an “additional insured” and provide Veracyte with a certificate of insurance promptly upon Veracyte’s request.

 

SECTION 11 - TERM AND TERMINATION

 

11.1                        Term.  This Agreement shall commence on the Effective Date and shall continue in force for a period of five (5) years (the “Initial Term”).  Upon expiry of the Initial Term, this Agreement shall terminate without any notice of termination being required, unless the parties agree in writing to extend the Agreement for an additional period to be agreed upon in writing by the parties (the “Extended Term”). At least six (6) months prior to expiry of the Initial Term, the parties will discuss the desirability of an Extended Term.

 

11.2                        Termination for Breach.  Without prejudice to the rights and remedies of Veracyte and Genzyme under this Agreement, either party may terminate this Agreement immediately by written notice to the other party if the other party either commits a breach of this Agreement or otherwise defaults in the performance of any of its duties or obligations

 

39

 

under this Agreement and such breach is not caused by a force majeure (as described in Section 12.3) and (i) such breach or default is material and curing such breach or default is temporarily or permanently impossible, or (ii) in all other cases if the breach is not remedied within thirty (30) days after receipt of written notice of termination pursuant to this Section 11.2.

 

11.3                        Termination for Insolvency.  Either party may terminate this Agreement effective immediately by written notice to the other party if the other party:

 

(a)                                 becomes insolvent, or has filed a request to be declared insolvent, or has been granted moratorium on payment;

 

(b)                                 makes an assignment for the benefit of creditors;

 

(c)                                  ceases to do business;

 

(d)                                 commences any dissolution, liquidation or winding up; or

 

(e)                                  has a receiver, trustee administrator or examiner or liquidator appointed over all or a substantial part of its assets.

 

11.4                        Termination Upon Change of Control.  Either party will have the right to immediately terminate this Agreement by written notice to the other party in the event of a Change of Control of the other party.  A party shall provide notice to the other party not less than sixty (60) days prior to its proposed Change of Control; provided, however, that if the party undergoing the Change of Control is advised by its legal counsel that it is precluded from providing the other party with this prior notice under applicable laws or regulations, then the party undergoing the Change of Control shall deliver such notice immediately after consummation of the Change of Control.  The above notice shall contain the following information regarding the person or entity that will assume control:

 

(a)                                 the name and legal composition of the person or entity;

 

(b)                                 financial information regarding such person or entity; and

 

(c)                                  a general description of the transfer transaction.

 

In addition, the party that is subject to the Change of Control shall provide the other party with such other information as may be reasonably requested by that party after the receipt of such notice.

 

11.5                        Termination for Convenience.  Except as may be provided otherwise in Exhibit A, beginning on the third (3rd) anniversary of the Effective Date, either party will have the right to terminate this Agreement on a Country-by-Country basis without cause: (i) by giving the other party six (6) months prior written notice and (ii) if such termination is by Veracyte, by paying the termination fee, if any, provided in Exhibit A.  For the purposes of clarity, it is the understanding of the parties that during the notice period described

 

40

 

above, the rights and obligations of the parties shall continue in full force and effect until the applicable date of termination of the Agreement.

 

11.6                        Termination by Genzyme on a Country-by-Country Basis for Regulatory Action.

 

11.6.1              Within sixty (60) days following the occurrence of a Country Regulatory Event, Genzyme may provide Veracyte with written notice of such Country Regulatory Event (a “CRE Notice”).  Such CRE Notice shall provide details regarding the event that constitutes a Country Regulatory Event, the date of such occurrence and the basis for why any Country Regulatory Event could constitute a Qualified Country Regulatory Event.  Upon the receipt of a CRE Notice, Veracyte will have six (6) months to work in good faith to resolve, cure, or abate such Country Regulatory Event to the reasonable satisfaction of Genzyme.  If Veracyte is unable to resolve, cure or abate such Country Regulatory Event during such six (6) month period and such Country Regulatory Event constitutes a Qualified Country Regulatory Event, then Genzyme will have the right, no later than eight (8) months following the occurrence of such a Qualified Country Regulatory Event, to terminate any further rights and obligations under this Agreement with regards to such Country, with thirty (30) days prior written notice to Veracyte (a “Country Regulatory Termination”).

 

11.6.2              For the purposes of clarity, it is the understanding of the parties that during any notice period described above prior to the effective date of a Country Regulatory Termination, the rights and obligations of the parties shall continue in full force and effect until the applicable date of termination rights and obligations regarding such Country.

 

11.6.3              If Genzyme elects to exercise such Country Regulatory Termination right with regards to a Country, no further CS Royalties, DPO Promotion Fees or LC Promotion Fees, as applicable, will be payable for Net Revenues achieved in such Country after the effective date of the Country Regulatory Termination for such Country.

 

11.6.4              Any Country for which Genzyme terminates its rights and obligations pursuant to this Section 11.6 shall be automatically become a Removed Country as of the effective date of such termination.

 

11.6.5              For purposes of this Section 11.6:

 

(a)                                 “Country Regulatory Event” shall mean, with respect to any Country, the occurrence of any of the following: (1) any Regulatory Authority in that Country pursuing an enforcement action (i) against Veracyte or its Affiliates (to the extent that such Affiliates are offering the Test pursuant this Agreement in such Country) that impacts the ability to commercialize the Test or (ii) directly related to the Test; or (2) any Regulatory Authority in that Country issuing a warning letter (i) against Veracyte or its Affiliates (to the extent that such Affiliates are providing services to

 

41

 

Genzyme pursuant to this Agreement in such Country) that impacts the ability to commercialize the Test or (ii) directly related to the Test; and

 

(b)                                 “Qualified Country Regulatory Event” shall mean a Country Regulatory Event that both (a) materially and adversely affects the ability of the parties to commercialize the Test in the Country where the Country Regulatory Event occurs, and (b) leads to the actual average monthly volume of FNAs received by Veracyte for the Test in such Country during the six (6) months following the date of the occurrence of the Country Regulatory Event being at least fifty percent (50%) less than the average monthly volume for the six (6) months prior to such date.

 

11.7                        Termination by Veracyte on a Country-by-Country Basis for Failure to Maintain Sales Force.  In addition to any other remedies that may be available to Veracyte, if at any time (a) following twelve (12) months after Veracyte or Genzyme receives reimbursement from payers covering about twenty percent (20%) of the County’s population and any required Marketing Authorization for the Test in a Country, should Genzyme fail to use its Commercially Reasonable Efforts to (i) if such Country is in the Comprehensive Services Territory, market, promote, detail and sell the Test in any such Country as provided herein (other than due to a force majeure event, a recall, or a supply shortage) or (ii) if such Country is in the Dedicated Promotion Only Territory, market, promote and detail the Test in any such Country as provided herein (other than due to a force majeure event, a recall, or a supply shortage), or (b) following the Effective Date, should Genzyme fail to continue to employ a direct sales force in any Country, then, in either case, Veracyte will have the right to deliver a notice to Genzyme (a “Country Removal Notice”).  Such Country Removal Notice shall identify the Country (or Countries) where Veracyte reasonably believes in good faith that Genzyme failed to use its Commercially Reasonable Efforts to market, promote, detail and, if applicable, sell the Test or fail to continue to employ a direct sales force including sufficient detail for Genzyme to understand and attempt to cure its failure to perform and any information regarding the market opportunity in such Country.  Within one hundred twenty (120) business days following receipt of such Country Removal Notice, if Genzyme (i) has failed to undertake in good faith its obligations to use its Commercially Reasonable Efforts to market, promote, detail and, if applicable, sell the Test in the Country that is subject of such Country Removal Notice, and (ii) such failure is not due primarily to any breach of this Agreement by Veracyte, then such Country shall be a Removed Country.  For purposes of clarity, Genzyme will not be owed any additional DPO Promotion Fees and Veracyte will not be owed any additional CS Royalties with regard to such Removed Country based on Net Revenue recognized from such Country on and after the date such Country becomes a Removed Country.

 

11.8                        Effects of Expiration or Termination.

 

11.8.1              Notwithstanding anything to the contrary in this or any other agreement between the parties, all rights and obligations of the parties set forth herein that expressly or by their nature survive expiration or termination of this Agreement (or survive termination of the rights and obligations with regards to a particular Country

 

42

 

under this Agreement) (including without limitation Sections 1, 3.4, 3.6.1 (last sentence), 3.7, 6.2, 6.3, 7, 9.8, 10, 11.8, and 12) shall continue in full force and effect subsequent to and notwithstanding the expiration or termination of this Agreement until they are satisfied or by their nature expired and shall bind the parties and their legal representatives, successors, and permitted assigns.

 

11.8.2              Expiration or termination of this Agreement for any reason shall be without prejudice to the rights and remedies of either party with respect to any antecedent breach of any of the provisions of this Agreement.

 

11.8.3              Upon termination of this Agreement, Genzyme shall cooperate in good faith with Veracyte or its designee in transitioning all customer support, promotional and other activities and responsibilities for the Test in the Territories, as set forth hereunder, to Veracyte or its designee as requested by Veracyte.  The parties agree to cause such transition to occur as quickly as practicable after the effective date of such termination.  After expiration or termination of this Agreement, Veracyte shall retain the right to use any training materials and Ad/Prom Materials related to the Test developed during the Term; provided, however, that Veracyte shall have no further right to use Genzyme’s name or Trademarks.

 

11.9                        Dispute Resolution.  In the event of any dispute arising between the parties relating to, arising out of, or in any way connected with this Agreement or any term or condition hereof, or the performance by either party of its obligations hereunder, such dispute shall be referred to the Steering Committee and the parties shall follow the dispute resolution procedures set forth in Section 5.3 hereof.

 

SECTION 12 - MISCELLANEOUS PROVISIONS

 

12.1                        Independent Status of the Parties.  Veracyte and Genzyme are independent entities each acting in its own name of for its own account.  Without explicit prior written authorization, neither party shall have the authority to bind, commit or incur any liability on behalf of the other party or to otherwise act in any way as an agency, representative or partner of the other party.

 

12.2                        Assignment.  This Agreement shall not be assigned or otherwise transferred by either party without the prior written consent of the other party; provided, however, that either party may assign this Agreement to any of its Affiliates or to a successor to the portion of its business related to this Agreement (whether by merger, a sale or transfer of all or substantially all of its assets relating to this Agreement, a sale of its capital stock, or otherwise), including, in the case of Genzyme, the transfer to an Affiliate of the entire sales and marketing organization used to promote, market and detail Thyrogen.  Subject to the foregoing, this Agreement shall be binding upon and inure to the benefit of the parties hereto and their respective permitted successors and assigns.

 

12.3                        Force Majeure.  The performance of either party under this Agreement may be suspended to the extent and for the period of time that such party is prevented or delayed from fulfilling its obligations due to causes beyond its reasonable control (including, without

 

43

 

limitation, acts of God, acts of civil or military authority including governmental priorities, strikes or other labor disturbances, fires, floods, epidemics, wars, terrorism, or riots); provided, however, that the non-performing party uses Commercially Reasonable Efforts to avoid or remove such causes of non-performance and continues performance hereunder with reasonable dispatch as soon as such causes are removed.  After thirty (30) consecutive calendar days of suspension on the part of one party, the other party may, at its sole discretion, terminate this Agreement without further liability.

 

12.4                        Severability.  To the extent any clause, term or provision of this Agreement shall be judged to be invalid or unenforceable for any reason whatsoever, such invalidity or unenforceability shall not affect the validity or enforceability of the balance of such clause, term or provision or any other clause, term or provision hereof.  The remaining provisions of this Agreement will remain binding and enforceable, and shall be interpreted so as best to reasonably effect the intent of the parties.  The parties further agree that any such invalid or unenforceable provisions will be deemed replaced with valid and enforceable provisions that achieve, to the extent possible, the business purposes and intent of such invalid and unenforceable provisions.

 

12.5                        Governing Law and Jurisdiction.  This Agreement shall be governed by and construed in accordance with the laws of the state of New York, including all matters of construction, validity, performance and enforcement.

 

12.6                        Relationship of Parties.  The parties hereto are acting and performing as independent contractors, and nothing in this Agreement creates the relationship of partnership, joint venture, sales agency or principal and agent.  Neither party is the agent of the other, and neither party may hold itself out as such to any other person.  All financial obligations associated with each party’s business shall be the sole responsibility of such party.

 

12.7                        Public Announcements.  The form and content of any public announcement to be made by one party regarding the execution or existence of this Agreement, or the subject matter contained herein, shall be subject to the prior written consent of the other party (which consent shall not be unreasonably withheld, delayed or conditioned), except as may be required by applicable law (including, without limitation, disclosure requirements of the SEC, NYSE, or any other stock exchange or NASDAQ), in which case the party making the disclosure shall give the other party reasonable advance notice and review of any such disclosure.  Following the dissemination of such initial public announcement, neither party (nor any of their Affiliates) shall issue any press release or make any public announcement with respect to this Agreement and the transactions contemplated hereby without prior consultation with the other party, except as may be required by applicable law upon the advice of counsel.  Each party shall provide the other party with a reasonable opportunity to review the release or other public announcement prior to disclosure.  Notwithstanding the foregoing, each the parties may each disclose to third parties the information contained in any press release that was previously approved by both of the parties without the need for further approval by the other party.

 

12.8                        No Implied Licenses.  Each of the parties hereby acknowledges and agrees that, except as otherwise explicitly provided in this Agreement, it does not have, assert or acquire any

 

44

 

right, title or interest in or to any Intellectual Property Rights or other proprietary rights of the other party or its Affiliates by entering into this Agreement.

 

12.9                        Notices.  All notices hereunder shall be delivered as follows: (a) personally; (b) by facsimile and confirmed by either first class mail (postage prepaid) or overnight courier service; (c) by registered or certified mail (postage prepaid); or (d) by overnight courier service, to the following addresses of the respective parties:

 

	
If to   Genzyme:
    	
With   a copy to:
    
	
 
    	
 
    
	
Genzyme   Corporation
    	
Genzyme   Corporation
    
	
500 Kendall   Street
    	
500 Kendall   Street
    
	
Cambridge, MA   02142
    	
Cambridge, MA   02142
    
	
Attention:   General Manager, Endocrine Business
    	
Attention:   General Counsel
    
	
Facsimile:   (617) 761-8667
    	
Facsimile: (617) 252-7553
    

 

	
If to   Veracyte:
    	
With   copy to:
    
	
 
    	
 
    
	
Veracyte, Inc.
    	
Veracyte, Inc.
    
	
7000   Shoreline Court, Suite 250
    	
7000   Shoreline Court, Suite 250
    
	
South   San Francisco, CA 94080
    	
South   San Francisco, CA 94080
    
	
Attention:   Chief Executive Officer
    	
Attention:   General Counsel
    
	
Facsimile:   (650) 243-6301
    	
Facsimile:   (650) 243-6301
    

 

Notices shall be effective upon receipt if personally delivered or delivered by facsimile and confirmed by first class mail, on the third business day following the date of registered or certified mailing, or on the first business day following the date of delivery to the overnight courier.  A party may change its address listed above by written notice to the other party.

 

12.10                 Exchange Controls.  All payments due hereunder shall be paid in United States dollars.  If at any time legal restrictions prevent the prompt remittance of part or all payments with respect to any Country in which the Test is sold, payment shall be made through such lawful means or methods as the parties may determine in good faith.

 

12.11                 Entire Agreement.  This Agreement, together with the Exhibits hereto, contains the entire understanding of the parties with respect to the subject matter hereof.  All express or implied agreements and understandings, either oral or written, heretofore made are expressly merged in and made a part of this Agreement, including without limitation the Letter of Agreement (including without limitation Exhibit A thereto) dated November 7, 2014 but excluding the Joint Defense Agreement dated as of January 28, 2011, which shall continue in full force and effect in accordance with its terms.  This Agreement may be amended, or any term hereof modified, only by a written instrument duly executed by both parties hereto.  Each of the parties hereby acknowledges that this Agreement is the

 

45

 

result of mutual negotiation and therefore any ambiguity in their respective terms shall not be construed against the drafting party.

 

12.12                 Headings.  The captions to the several Sections hereof are not a part of this Agreement, but are merely guides or labels to assist in locating and reading the several Sections hereof.

 

12.13                 Waiver.  Except as expressly provided herein, the waiver by either party hereto of any right hereunder or of any failure to perform or any breach by the other party shall not be deemed a waiver of any other right hereunder or of any other failure to perform or breach by said other party, whether of a similar nature or otherwise, nor shall any singular or partial exercise of such right preclude any further exercise thereof or the exercise of any other such right.

 

12.14                 Counterparts.  This Agreement may be executed in two or more counterparts, each of which shall be deemed an original, but all of which together shall constitute one and the same instrument.  Signature pages may be exchanged by facsimile.

 

[Signature page to follow]

 

46

 

IN WITNESS WHEREOF, Veracyte and Genzyme have each caused this Agreement to be executed by their respective duly authorized officers.

 

	
VERACYTE, INC.
    	
 
    	
GENZYME CORPORATION
    
	
 
    	
 
    	
 
    
	
 
    	
 
    	
 
    
	
/s/   Bonnie Anderson
    	
 
    	
/s/   David Meeker
    
	
Bonnie   Anderson
    	
 
    	
David   Meeker
    
	
Chief   Executive Officer
    	
 
    	
Chief   Executive Officer
    
	
 
    	
 
    	
 
    
	
Date:   February 13, 2015
    	
 
    	
Date:   February 13, 2015
    

 

[SIGNATURE PAGE TO EX-U.S. CO-PROMOTION AGREEMENT]

 

 

*** Confidential material redacted and filed separately with the Commission.

 

EXHIBIT A

 

Country Specific Terms

 

1.              Brazil

 

a.              Territory: Dedicated Promotion Only Territory

 

b.              Genzyme Activities: Genzyme will promote the Test through current Thyrogen CSAs at the same call points as Thyrogen. Genzyme will provide limited training.

 

c.               Veracyte Activities: Veracyte will be responsible for performing the Test, managing clinical studies, billing and reimbursement. Veracyte will cover expenses, including the cost of materials.

 

d.              Country Payment Rate: Veracyte will pay twenty-five percent (25%) of Net Revenue over a five (5) year period commencing on January 1, 2015.

 

e.               Country Commitment Date: January 1, 2015.

 

f.                Account Management: Veracyte, either itself or through its subcontractors, will be solely responsible for Healthcare Professional account conversion and set-up, account management and account support.

 

g.               Sampling Program: Veracyte, either itself or through its subcontractors, will manage and provide a sampling program for the Test in which Veracyte will provide Collection Kits to Healthcare Professionals in accordance with the Annual Commercial Plan.

 

h.              Sales Force: *** FTEs in Genzyme’s sales force.

 

i.                  Marketing Authorization: Genzyme will hold the ANVISA registration for the Test in Brazil.

 

j.                 Termination Fee:  If, pursuant to Section 11.5, Veracyte terminates this Agreement with respect to Brazil, and if Veracyte generates at least one hundred (100) Afirma Gene Expression Classifier billable results during the twelve (12) months immediately prior to the notice of termination, then Veracyte will pay to Genzyme $300,000 if the termination takes place in the fourth year of the agreement and $200,000 if the termination takes place in the fifth year of the agreement.  Veracyte shall pay the termination fee within sixty (60) days of the termination effective date.  If such billable Afirma Gene Expression Classifier billable results have not been obtained, Veracyte shall not be required to pay any termination fee to Genzyme.

 

 

*** Confidential material redacted and filed separately with the Commission.

 

2.              Singapore

 

a.              Territory: Dedicated Promotion Only Territory

 

b.              Genzyme Activities: Genzyme will promote the Test through current Thyrogen CSAs at the same call points as Thyrogen in Singapore. Genzyme will provide limited training.

 

c.               Veracyte Activities: Veracyte will be responsible for performing the Test, managing clinical studies, billing and reimbursement. Veracyte will cover expenses, including the cost of materials.

 

d.              Country Payment Rate: Veracyte will pay twenty-five percent (25%) of Net Revenue over a five (5) year period for billable tests received from Parkway clinics in Singapore, Malaysia, Thailand, Philippines, Vietnam, Brunei, Myanmar, Cambodia or Indonesia commencing on January 1, 2015.

 

e.               Country Commitment Date: January 1, 2015.

 

f.                Account Management: Veracyte, either itself or through its subcontractors, will be solely responsible for Healthcare Professional account conversion and set-up, account management and account support.

 

g.               Sampling Program: Veracyte, either itself or through its subcontractors, will manage and provide a sampling program for the Test in which Veracyte will provide Collection Kits to Healthcare Professionals in accordance with the Annual Commercial Plan.

 

h.              Sales Force: *** FTEs in Genzyme’s sales force.

 

i.                  Termination Fee:  None.

 

 

EXHIBIT B

 

Trademarks

 

“Veracyte” and “Afirma” are registered Trademarks of Veracyte.

 

“Genzyme” and “Thyrogen” are registered Trademarks of Genzyme.

 

 

*** Confidential material redacted and filed separately with the Commission.

 

EXHIBIT C

 

Veracyte Patents & Patent Applications (U.S.)

 

	
Application
   Number
    	
 
    	
Application
   Date
    	
 
    	
Publication Number
    	
 
    	
Publication
   Date
    	
 
    	
Title
    
	
61/199,585
    	
 
    	
11/17/2008
    	
 
    	
Not Yet Available
    	
 
    	
Not Yet Available
    	
 
    	
Methods and   Compositions of Molecular Profiling for Diagnosis of Cancer
    
	
61/270,812
    	
 
    	
7/13/2009
    	
 
    	
Not Yet Available
    	
 
    	
Not Yet Available
    	
 
    	
Methods and   Compositions of Molecular Profiling for Diagnosis of Cancer
    
	
12/592,065
    	
 
    	
11/17/2009
    	
 
    	
US2010/0131432
    	
 
    	
5/27/2010
    	
 
    	
Methods and   Compositions of Molecular Profiling for Disease Diagnostics
    
	
***
    	
 
    	
***
    	
 
    	
Not Yet Available
    	
 
    	
Not Yet Available
    	
 
    	
***
    
	
***
    	
 
    	
***
    	
 
    	
Not Yet Available
    	
 
    	
Not Yet Available
    	
 
    	
***
    
	
61/176,471
    	
 
    	
5/7/2009
    	
 
    	
Not Yet Available
    	
 
    	
Not Yet Available
    	
 
    	
Methods and   Compositions for Diagnosis of Thyroid Conditions
    
	
13/318,751
    	
 
    	
11/3/2011
    	
 
    	
Not Yet Available
    	
 
    	
Not Yet Available
    	
 
    	
Methods and   Compositions for Diagnosis of Thyroid Conditions
    
	
61/333,717
    	
 
    	
5/11/2010
    	
 
    	
Not Yet Available
    	
 
    	
Not Yet Available
    	
 
    	
Molecular   Classification of Thyroid Nodules Using High-Dimensionality Genomic Data
    
	
***
    	
 
    	
***
    	
 
    	
Not Yet Available
    	
 
    	
Not Yet Available
    	
 
    	
***
    
	
61/389,810
    	
 
    	
10/5/2010
    	
 
    	
Not Yet Available
    	
 
    	
Not Yet Available
    	
 
    	
Methods and   Compositions for Diagnosing Conditions
    
	
13/105,756
    	
 
    	
5/11/2011
    	
 
    	
Not Yet Available
    	
 
    	
Not Yet Available
    	
 
    	
Methods and   Compositions for Diagnosing Conditions
    
	
61/568,870
    	
 
    	
12/9/2011
    	
 
    	
Not Yet Available
    	
 
    	
Not Yet Available
    	
 
    	
Methods and   Compositions for Classification of Samples
    
	
***
    	
 
    	
***
    	
 
    	
Not Yet Available
    	
 
    	
Not Yet Available
    	
 
    	
***
    

 

 

EXHIBIT D

 

Customer Support

 

1.              In each Country, Veracyte will provide reasonable first level customer support to end users for the Test.

 

2.              In each Country, Veracyte will provide a dedicated phone line for end users to call.  Opening hours of the hot line will be adapted for local needs.  Call hours will be mutually determined.

 

	
Item
    	
 
    	
Description
    
	
Coverage   Time
    	
 
    	
International   : 8:00 AM to 5:00 PM (GMT+02:00) Mon- Thu office hours.
    
	
Service   Language
    	
 
    	
Local   languages in each Country
    
	
Recall   time in during coverage time
    	
 
    	
Within   3 hours
    
	
Initial   Response time
    	
 
    	
Within   24 hours
    
	
Number   of incidents
    	
 
    	
Unlimited
    

 

 

EXHIBIT E

 

Pharmacovigilance

 

Veracyte will report Safety Information pertaining to the Subject Products in accordance with the procedures described in this Exhibit E.  These procedures do not restrict Genzyme’s ability to take any action it deems appropriate or required under applicable law or regulations.

 

SECTION 1 - DEFINITIONS

 

1.1                               “Adverse Event” shall mean any untoward medical occurrence in a patient or clinical investigation subject using a Subject Product, whether or not related to the Subject Product.

 

1.2                               “Safety Information” shall mean all information on the Subject Products relating to known or potential risks to humans obtained or otherwise received from any source. This includes but is not limited to:

 

(a)                                 any reported deaths of patients, Adverse Events and incidents (see definitions below), irrespective of any suspected causal relationship to the Subject Product;

 

(b)                                 any information (regardless of the fact whether it is associated or not with an Adverse Event) regarding Misuse, Abuse, medication errors, Overdose, lack of efficacy, Off-Label Use, potential transmission of infectious agent via the Subject Product and Occupational Exposure;

 

(i)                                     “Overdose” shall mean the administration of a quantity of a medicinal product given per administration or cumulatively, which is above the maximum recommended dose according to the authorized product information.

 

(ii)                                  “Off-Label Use” shall mean situations where the medicinal product is intentionally used for a medical purpose not in accordance with the authorized product information.

 

(iii)                               “Misuse” shall mean situations where the medicinal product is intentionally and inappropriately used not in accordance with the authorized product information.

 

(iv)                              “Abuse” shall mean the persistent or sporadic, intentional excessive use of a medicinal product, which is accompanied by harmful physical or psychological effects.

 

(v)                                 “Occupational Exposure” shall mean the exposure to a medicinal product, as a result of one’s professional or non-professional occupation.

 

 

(c)                                  any exposure of pregnancy to the Subject Product via the mother, father or both;

 

(d)                                 any information related to studies initiated by independent investigators (“IST”), e.g. also inclusive of awareness of:

 

(i)                                     study protocol amendments for safety reasons or any other safety information related to IST;

 

(ii)                                  other changes to the conduct of the study, its procedures or study documents for safety reasons; or

 

(iii)                               results of assessment of partial or complete safety data or benefit-risk assessments or medical opinions related to an IST regardless by whom (external to Genzyme) these assessments were performed or medical opinions were given; and

 

(e)                                  any Safety Information associated with a suspected or confirmed counterfeit Subject Product.

 

SECTION 2 — TRANSMISSION OF SAFETY INFORMATION AND FOLLOW-UP

 

2.1                               Veracyte shall transmit Safety Information in or coming into its possession or control to Genzyme within twenty-four (24) hours after receiving such information via e-mail. Veracyte shall provide the following information: patient identifiers, reporter name and contact information, the Subject Product(s) (drug, dose, route, date of administration), and information regarding the Adverse Event to Genzyme by email in any of the following forms: (i) CIOMS I, (ii) Med Watch, (iii) AE reporting form (electronic or hardcopy) or (iv) any other form specifically agreed to between Veracyte and Genzyme in writing. The communication shall be in English and all such documents shall be in an electronic format that allows for “copy & paste” of the Safety Information from the document into the Genzyme safety database. Such communications should be directed from the relevant Veracyte contact person indicated below, by specifying date of receipt and contact details from the complainant (to allow Genzyme to follow up), to:

 

Email: cl-Partners-CPV@sanofi.com

 

Veracyte Contact Person:

Kevin Lenn

Kevin@veracyte.com

650-243-6330

 

2.2                               Veracyte will provide monthly listings of any Safety Information received during the month from all sources and countries for reconciliation purposes.  The reconciliation report will include both initial and follow-up Safety Information and will include Veracyte’s report identifiers. The reconciliation report format will be agreed by

 

 

Genzyme. The report will include information which meets the criteria for Safety Information as defined above in Section 1.

 

2.3                               Genzyme, as the holder of the Marketing Authorization(s) for the Subject Product(s), shall be responsible for the investigation and follow-up of Individual Case Safety Reports (“ICSRs”), for submitting expedited and periodic safety reports to Regulatory Authorities in accordance with applicable laws, and for responding to all local Regulatory Authority’s queries.

 

SECTION 3 -  RECORDS

 

3.1                               VERACYTE shall establish and maintain:

 

(a)                                 adequate policies and Standard Operating Procedures to ascertain compliance with the obligations towards the transmission of Safety Information as stipulated under Section 2 above. Veracyte will disclose any of such policies and/or Standard Operating Procedures to Genzyme when requested; and

 

(b)                                 job descriptions and training records for personnel having responsibilities in respect of the handling of Safety Information for the Subject Products.

 

3.2                               Veracyte shall make the records as described above in Section 3.1 available to Genzyme and to any third party designated by Genzyme, and shall provide copies of these records to Genzyme and/or any third party designated by it, within three (3) business days of receiving a request for such records.

 

3.3                               Veracyte shall maintain the records as described above in Section 3.1 for a period of at least three (3) years after the expiration or termination of the Agreement, or such longer period as may be required by law.

 

SECTION 4 — TRAINING

 

4.1                               Veracyte shall ensure training to its personnel involved in the handling of Safety Information within a reasonable period following the Effective Date, to ensure compliance with the procedures contained in this Exhibit E.  Veracyte agrees to ensure that all relevant members of their staff are adequately kept informed on the processes for the handling of Safety Information, as defined in this Exhibit E and in any subsequent amendment thereto.

 

SECTION 5 — AUDIT

 

5.1                               Genzyme, or an Affiliate on its behalf, has the right to audit Veracyte’s pharmacovigilance records to confirm compliance with the relevant provisions hereof and of applicable law.  Such audit may be either a documentary audit or otherwise, and will be performed at reasonable times and places, upon reasonable notice, and at Genzyme’s sole expense, either with Genzyme or an Affiliate’s internal auditors or other individuals or a third party qualified by experience; provided that any third party

 

 

is reasonably acceptable to vendor.  Veracyte agrees to provide Genzyme, or an Affiliate on its behalf, with access to relevant systems, documentation and individuals for purposes of conducting the audit.Exhibit 10.10

 

SEPARATION, NON-COMPETITION AND
CONSULTING AGREEMENT

 

THIS SEPARATION, NON-COMPETITION
AND CONSULTING AGREEMENT (the “Agreement”) is made this 2nd day of March, 2015, by and between WSFS Financial Corporation
(the “WSFS”), Alliance Bancorp, Inc. of Pennsylvania (“Alliance”), and Dennis D. Cirucci (the “Executive”)
on the terms and conditions set forth below:

 

WHEREAS, the Executive
has been employed by Alliance and will remain an employee of Alliance through the closing of the merger (the “Merger”)
and the other transactions contemplated by the Agreement and Plan of Reorganization by and between WSFS and Alliance, dated March
2, 2015 (the “Merger Agreement”);

 

WHEREAS, Alliance,
WSFS and their respective affiliates are engaged in the business of acting as a commercial or retail banking business (the “Business”);

 

WHEREAS, the Executive
will terminate his employment with Alliance effective and contingent upon the closing of the Merger (the “Termination Date”);

 

WHEREAS, the Executive
has agreed to become a consultant to WSFS for a period of six (6) months, effective and contingent upon the closing of the Merger;

 

WHEREAS, the Executive,
Alliance and WSFS wish to settle, compromise and resolve any and all claims that the Executive may have against Alliance and/or
WSFS, including claims under the Executive’s employment agreement with Greater Delaware Valley Savings Bank (doing business
as Alliance Bank) dated December 17, 2014 (the “Employment Agreement”), in order to facilitate completion of the Merger;
and

 

WHEREAS, WSFS has,
as part of this agreement, agreed to provide the Executive with certain special benefits that it was not otherwise obligated to
provide, including that WSFS will not dispute the Executive’s claim that he has “Good Reason” (as that term is
defined in the Employment Agreement) to terminate employment as of the Termination Date.

 

NOW THEREFORE, the
Executive, Alliance, and WSFS hereby agree to the following:

 

1.Effective
Date and Contingency. This Agreement shall be effective upon the closing of the Merger. None of the parties to this Agreement
shall have any rights or obligations set forth in this Agreement before it becomes effective. This Agreement shall be null and
void if, and at such time as, the Merger Agreement is terminated and the Merger is abandoned for any reason prior to the Effective
Time of the Merger (as defined in the Merger Agreement).

 

2.Separation
from Employment. The Executive’s employment with Alliance shall terminate as of the Termination Date. Alliance will pay
the Executive all salary and vacation benefits payable through the Termination Date, subject to standard withholdings and deductions,
in accordance with its normal payroll processes. 

 

3.Compensation
and Benefits. WSFS agrees to provide the Executive with the following payments and benefits in connection with his termination
of employment and in exchange for the promises and releases made by the Executive within this Agreement:

 

    	 

    	 

    

 

(a)WSFS shall pay
the Executive a lump sum payment in the amount of $990,687, subject to deductions and withholdings that WSFS determines are required
by law (the “Separation Payment.”). The Separation Payment will be made within ten (10) business days following the
Termination Date.

 

(b)(i) WSFS shall
enable the Executive to continue to participate, at no cost to the Executive, in all group insurance, life insurance, health and
accident insurance, and disability insurance plans maintained by WSFS on substantially similar terms as those offered by Alliance
immediately before the Termination Date. The Executive’s continued participation will continue until June 30, 2018, or, if
earlier, the date of the Executive’s full-time employment by another employer (provided that the Executive is entitled under
the terms of such employment to benefits substantially similar to those described in this subparagraph).

 

(ii)If the continued participation
of the Executive in any such group insurance plan is barred or would trigger the payment of an excise tax under Section 4980D of
the Internal Revenue Code (the “Code”), or during such period any such group insurance plan is discontinued, then WSFS
shall at its election either (i) arrange to provide the Executive with alternative benefits substantially similar to those which
the Executive was entitled to receive under such group insurance plans immediately prior to the Termination Date (provided that
the alternative benefits do not trigger the payment of an excise tax under Section 4980D of the Code), or (ii) pay to the Executive
within ten (10) business days following the Termination Date (or within ten (10) business days following the discontinuation of
the benefits if later) a lump sum cash amount equal to the projected cost to WSFS of providing continued coverage to the Executive,
with the projected cost to be based on the costs being incurred immediately prior to the Termination Date (or the discontinuation
of the benefits if later), as increased by 10% each year.

 

(iii)Any insurance premiums payable
by WSFS or any successor pursuant to this section shall be payable at such times and in such amounts as if the Executive was an
employee of WSFS, subject to any increases in such amounts imposed by the insurance company or COBRA, with WSFS paying the full
amount of such premiums, including any employee portion of the premiums that the Executive would have been required to pay if he
was an employee of WSFS. The amount of insurance premiums required to be paid by WSFS in any taxable year shall not affect the
amount of insurance premiums required to be paid by the WSFS in any other taxable year.

 

(c)WSFS shall pay
to the Executive, in a lump sum within ten (10) business days following the Termination Date, a cash amount equal to $63,268 pursuant
to Section 5(d)(v) of the Employment Agreement.

 

(d)WSFS shall transfer
to the Executive the title on the company-provided automobile currently used by the Executive. Such title transfer shall occur
within ten (10) business days following the Termination Date, without the payment of any consideration by the Executive.

 

(e)WSFS shall pay
to the Executive, in a lump sum within ten (10) business days following the Termination Date and in exchange for the promises made
by the Executive in paragraphs 5, 6 and 9 of this Agreement, a cash amount equal to $400,000.

 

4.No
Other Obligations. Except as set forth in the preceding paragraphs and except as required under any “Alliance Benefit
Plan” (as defined in the Merger Agreement), neither WSFS nor Alliance shall have any obligation to make any further payments
to or for the Executive’s benefit with respect to his services before the Termination Date.

 

    	- 2 -

    	 

    

 

5.Consulting.
During the six-month period beginning on the Termination Date, the Executive shall make himself available to provide consulting
services upon the reasonable request of WSFS. The parties hereto agree that the level of consulting services during such period
shall be at a level that is less than 20% of the average level of services provided by the Executive to Alliance and its subsidiaries
during the 36-month period immediately preceding the Termination Date and that the Executive shall have a “separation from
service” as defined in Section 409A of the Code as of the Termination Date.

 

6.Release.
The Executive agrees to sign a release substantially in the form attached as Exhibit A to this Agreement on the Termination Date.

 

7.Return
of Property. The Executive represents and covenants that he will return, on or before the expiration of the consulting period,
to WSFS all documents, other materials and property in his possession, custody or control that refer or relate to Alliance’s
or WSFS’s business, in whatever form, format or medium including, but not limited to papers, documents, letters, invoices,
notes, memoranda, keys, records, customer and supplier lists, customer and supplier materials or documents, computer hardware and
software, computer data, office equipment, and employment records, provided that mobile devices and laptops shall be retained by
the Executive after all employer-related data is removed in accordance with Alliance’s policies. Further, by executing this
Agreement, the Executive is certifying that any documents and other materials relating to Alliance and affiliated entities that
are stored on non-Alliance hardware or software within the Executive’s possession, custody or control have been returned
or will be returned, have not been and will not be duplicated or reproduced and have not been and will not be transmitted to third
parties, other than service providers to Alliance in the ordinary course and other than those identified by the Executive in writing
and disclosed to WSFS prior to the execution of the Agreement. 

 

8.Recognition
of Alliance’s and WSFS’s Legitimate Interests. The Executive acknowledges and agrees that Alliance has invested
substantial resources and time to developing the contacts and goodwill with its customers, potential customers, suppliers, vendors
and employees, all of which are highly valuable assets to Alliance and WSFS. The Executive acknowledges and agrees that Alliance
has spent and will continue to spend substantial effort, time and resources in developing and protecting its relationships with
its customers, potential customers, suppliers, vendors and employees. The Executive acknowledges and agrees that during the Executive’s
tenure with Alliance, the Executive has had access to and learned confidential and proprietary information relating to Alliance.
The Executive acknowledges and agrees that Alliance’s and WSFS’s competitors would obtain an unfair competitive advantage
if the Executive were to disclose Alliance’s or WSFS’s Confidential Information (as defined below) to a competitor,
used it on a competitor’s behalf, or if the Executive were able to exploit the relationships the Executive developed as an
employee of Alliance to solicit business on behalf of a competitor.

 

9.Non-Disclosure
of Confidential Information. 

 

(a)As used in this
Agreement, the term “Confidential Information” means any and all of Alliance’s trade secrets, confidential and
proprietary information and all other information and data of Alliance that is generally unknown to third persons who could derive
economic value from its use or disclosure including, but not limited to, non-public customer information, including customer lists,
customer requirements, customer needs, customer purchasing histories and customer sales trends; product and services cost pricing
and varying supplies and vendor information including costs, discount and rebate programs, logistics information; and operational,
financial and marketing information propriety to or held confidential by Alliance. Confidential Information may be contained in
writing or other tangible medium of expression, including work product created by the Executive in rendering services for Alliance.
The Executive acknowledges and agrees that the Confidential Information is a valuable, special and unique asset of Alliance and
WSFS.

 

    	- 3 -

    	 

    

 

(b)The Executive
will not use or disclose to others any of Alliance’s or WSFS’s Confidential Information, except as authorized in writing
by WSFS. The Executive agrees that Alliance owns the Confidential Information and the Executive has no rights, title or interest
in any of the Confidential Information.

 

(c)The Executive’s
confidentiality obligations shall continue as long as the Confidential Information remains confidential, and shall not apply to
any information that becomes generally known to the public through no fault or action of the Executive.

 

10.Post-Employment
Covenants. The Executive acknowledges and agrees that the following covenants are reasonably necessary to protect the legitimate
business interests of Alliance and WSFS, including the protection of Alliance’s and WSFS’s Confidential Information
and goodwill, and that these covenants are an essential part of and consideration for, this Agreement. 

 

(a)Nondisparagement.
The Executive agrees that he shall not make any negative public or private statements concerning Alliance, WSFS, any of their respective
affiliates or any of their respective officers, employees or members.

 

(b)Non-Compete.
The Executive hereby covenants and agrees that, for a period commencing on the Termination Date and terminating on the 18-month
anniversary of the Termination Date (the “Restricted Period”), such Executive shall not, within the Commonwealth of
Pennsylvania, the State of Maryland or within fifty (50) miles of 541 Lawrence Road, Broomall, Pennsylvania 19008, without WSFS’s
prior written consent, directly or indirectly, either for himself or for any other individual, corporation, partnership, limited
liability company, joint venture or other entity (each an “Entity” and collectively, the “Entities”) other
than for WSFS or its Affiliates, participate in any business (including, without limitation, any division, group or franchise of
a larger organization) that engages (or proposes to engage) in the Business; provided, that if, as of the date hereof, the Executive
holds not more than a 5% direct or indirect equity interest in such Entity, then the Executive may retain such ownership interest
without being deemed to “participate” in the Business conducted by such Entity. For purposes of this Agreement, the
term “participate” shall mean having more than a 3% direct or indirect ownership interest in any Entity, whether as
a sole proprietor, investor, owner, shareholder, partner, member, manager, joint venturer, creditor or otherwise, or rendering
any direct or indirect service or assistance to any individual, corporation, partnership, limited liability company, joint venture
and other business entity (whether as a director, officer, manager, member, supervisor, employee, agent, consultant or otherwise),
with respect to the Business.

 

(c)Non-Solicit
of Customers. The Executive covenants and agrees that during the period commencing on the Termination Date and terminating
on the two-year anniversary of the Termination Date, the Executive shall not directly or indirectly, as employee, agent, consultant,
director, equity holder, member, manager, partner or in any other capacity, without WSFS’s prior written consent (other than
for the benefit of WSFS or its Affiliates), solicit, contact, call upon, communicate with or attempt to communicate with any Person
that is or was a customer of Alliance (excluding general solicitations of the public that are not based in whole or in part on
any list of customers of Alliance) during the one-year period preceding the Closing Date for the purpose of engaging in opportunities
related to the Business or contracts related to the Business.

 

    	- 4 -

    	 

    

 

(d)Non-Solicit
of Employees. The Executive covenants and agrees that during the period commencing on the Termination Date and terminating
on the two-year anniversary of the Termination Date, the Executive shall not directly or indirectly, as employee, agent, consultant,
director, equity holder, member, manager, partner or in any other capacity, without the prior written consent of WSFS, solicit
or induce any employee of Alliance, WSFS or any of their respective subsidiaries to leave the employ of such entities (excluding
general solicitations of the public that are not based in whole or in part on any list of employees of such entities).

 

11.Breach.
In the event of a breach or threatened breach of paragraphs 9 or 10 hereof, the Executive agrees that WSFS shall be entitled to
injunctive relief in a court of appropriate jurisdiction to remedy any such breach or threatened breach, and the Executive acknowledges
that monetary damages would be inadequate and insufficient, such that a court may award equitable relief. 

 

12.Cooperation.
The Executive agrees and covenants that the Executive shall in good faith and to the best of the Executive’s ability, to
the extent reasonably requested, cooperate with and serve in any capacity requested by Alliance or WSFS in any employment or business
dispute, investigation, proceeding or pending or threatened litigation (together, “Litigation”) in which Alliance,
WSFS, any affiliate or any of their respective members, officers or employees is a party, and regarding which the Executive, by
virtue of the Executive’s employment with Alliance or consulting with WSFS, has knowledge or information. Such cooperation
and service in any such Litigation shall include, without limitation, acting as Alliance’s or WSFS’s representative,
on behalf of Alliance or WSFS, or refraining from acting against the interest of Alliance or WSFS, any affiliate or any of their
respective members, officers or employees. The Executive further agrees and covenants that, in any such Litigation, the Executive
shall, without the necessity for subpoena, provide in any jurisdiction in which Alliance or WSFS request, truthful testimony relevant
to said Litigation. In the event the Executive provides such services following the expiration of the consulting period, then he
shall be reimbursed for such services at a rate equal to his final base salary prior to the Termination Date computed on an hourly
basis.

 

13.No
Admission. Neither this Agreement nor anything contained herein shall be admissible in any proceeding as evidence of or an
admission by Alliance or WSFS of any violation of any law or regulation or of any liability whatsoever under any law or regulation.
Notwithstanding the foregoing, this Agreement may be introduced into a proceeding solely for the purpose of enforcing this Agreement.

 

14.Severability.
If any provision of this Agreement is illegal, invalid or unenforceable or is held to be illegal, invalid or unenforceable, the
Executive agrees that such provision shall be fully severable with respect to scope, time and geographic area, and this Agreement
and its terms in such lesser scope, time and geographic area shall be construed and enforced as if such unenforceable or invalid
provision had never been a part of this Agreement.

 

15.No
Waiver. No waiver by any party of any breach of, or of compliance with, any condition or provision of this Agreement by another
party shall be considered a waiver of any other condition or provision or of the same condition or provision at another time.

 

16.Acknowledgments
and Affirmations. The Executive affirms that he has not filed, caused to be filed or presently is a party to any claim against
Alliance or WSFS.

 

17.Complete
Agreement. This Agreement supersedes any and all prior agreements between the Executive and Alliance or WSFS, whether written
or oral, including the Employment Agreement, except that the following provisions of the Employment Agreement shall continue in
full force and effect: Section 6. Payment of Additional Benefits under Certain Circumstances; Section 20. Payment of Costs and
Legal Fees and reinstatement of Benefits; and Section 21. Indemnification. Except as set forth in the preceding sentence with respect
to various sections of the Employment Agreement, this Agreement sets forth the entire understanding of the parties as to the subject
matter contained herein and may be amended only in writing by the parties hereto. 

 

    	- 5 -

    	 

    

 

18.Governing
Law. This Agreement shall be governed by and construed in accordance with the laws of the State of Delaware (without regard
to conflict of laws principles) and any dispute pertaining to or arising out of this Agreement shall be brought only in the state
or federal courts located within the State of Delaware. Both parties irrevocably consent to the personal jurisdiction of the state
and federal courts located within the State of Delaware.

 

19.Counterparts.
This Agreement may be executed in counterparts, each of which shall be deemed an original and all of which taken together shall
constitute one and the same instrument.

 

20.Assignment.The
Executive represents and warrants that he has not assigned or in any other manner conveyed any right or claim that he has or may
have to any third party, and he shall not assign or convey to any assignee for any reason any right or claim covered by this Agreement,
this Agreement, or the consideration, monetary or other, to be received by him hereunder. Alliance or WSFS may assign their rights
and obligations under this Agreement to any third party at their discretion.

 

IN WITNESS WHEREOF,
Alliance, WSFS, and the Executive have signed this Agreement on the dates set forth below:

 

	WSFS	 	 	 	ALLIANCE
	 	 	 	 	 	 	 
	 	 	 	 	 	 	 
	 	 	 	 	 	 	 
	By:	 	/s/Rodger
    Levenson	 	By:	 	/s/Dennis D. Cirucci
	Name:	 	Rodger Levenson	 	Name:	 	Dennis D.
    Cirucci
	Title:	 	Executive Vice President
    and	 	Title:	 	President
    and Chief Executive
	 	 	Chief Commercial Banking
    Officer	 	 	 	Officer
	 	 	 	 	 	 	 
	 	 	 	 	 	 	 
	Dated:	 	March
    2, 2015	 	 	 	Dated:	 	March
    2, 2015
	 	 	 	 	 	 	 
	 	 	 	 	 	 	 
	EXECUTIVE	 	 	 	 
	 	 	 	 	 	 	 
	/s/Dennis
    D. Cirucci	 	 	 	 
	Dennis D.
    Cirucci	 	 	 	 
	 	 	 	 	 	 	 
	 	 	 	 	 	 	 
	Dated:	 	March
    2, 2015	 	 	 	 

 

    	- 6 -

    	 

    

 

EXHIBIT A 

RELEASE

 

I, Dennis D. Cirucci,
on behalf of myself and my heirs, executors, administrators and assigns, hereby release, waive and forever discharge Alliance,
WSFS, their affiliates, predecessors, successors, parent company or assigns, and their respective directors, officers, trustees,
employees, representatives and agents (the “Released Parties”) from, and agree not to sue or bring any other action
against all or any of the Released Parties based on, any past or present duties, or responsibilities of any of the Released Parties,
and any and all claims or liabilities of whatever kind or nature, that I ever had or which I now have, at the time of or prior
to my execution of this release, known or unknown, including, but not limited to, claims in tort or contract; breach of fiduciary
duty; defamation; emotional distress; wrongful or unlawful discharge; claims for bonuses, severance pay, vacation leave, employee
or fringe benefits, or other compensation; and claims based on any state or federal wage, employment or common laws, statutes or
amendments thereto, including, but not limited to: (a) age discrimination claims under the Age Discrimination in Employment Act
(“ADEA”), 29 U.S.C. § 621 et seq. as amended by the Older Workers Benefit Protection Act; (b) any
race, color, religion, sex or national origin discrimination claims under Title VII of the 1964 Civil Rights Act, 42 U.S.C. § 2000(e)
et seq.; (c) any claim under the Americans with Disabilities Act (“ADA”), 42 U.S.C. § 12101
et seq.; (d) claims under the Employee Retirement Income Security Act of 1974, as amended (“ERISA”),
29 U.S.C. § 1001 et seq. (excluding claims for vested benefits); (e) any claim under the National Labor Relations
Act (“NLRA”), 29 U.S.C. § 151 et seq.; (f) claims under the Worker Adjustment and Retraining Notification
Act (“WARN”), 20 U.S.C. § 2101 et seq.; (g) claims under any state discrimination in employment
statute; (h) any claims related to or arising out of the Executive entering into this Agreement; (i) any claims related to or arising
out of the Executive’s former employment with and the termination of the Executive’s employment and separation from
Alliance or WSFS, including but not limited to a claim for wrongful discharge in violation of public policy; or (j) any claims
for damages due to personal injury or for compensatory or punitive damages.

 

Notwithstanding any
provision of this release to the contrary, (y) nothing contained herein shall be deemed to modify, waive, release, terminate or
amend any right or benefit the Executive may possess under the terms of the Separation, Non-Competition and Consulting Agreement
(the “Agreement”) or the terms of the Employment Agreement preserved by Section 17 of the Agreement, and (z) the Executive
does not waive or release any right that the Executive may have related to (i) vested benefits under any Alliance Benefit Plan,
(ii) any breach of the Agreement, (iii) any claim or right that may arise after the Executive signs this release, (iv) any accrued
but unused compensation as of the Termination Date, (v) his rights as a stockholder, depositor or borrower of Alliance or WSFS,
(vi) his rights as the holder of unexercised stock options to purchase common stock of Alliance, or (vii) any right or benefit
that cannot be waived as a matter of law.

 

I specifically acknowledge
and represent that: (a) I have been given a period of at least forty-five (45) days to consider the terms of this release, (b)
the terms of this release are clear and understandable, (c) the benefits that WSFS and Alliance are providing to me under the Separation
and Consulting Agreement to which this release is attached exceed the benefits that I was otherwise entitled to receive as an employee
of Alliance or WSFS, (d) I have been advised to consult with an attorney of my choice prior to signing this release, and (e) I
have been advised that I have the right to revoke this release at any time within the seven (7) day period following the date on
which I sign the release.

 

All capitalized terms
which are defined in the Agreement and which are not otherwise defined herein shall have the meaning set forth in the Agreement.

 

    	 

    	 

    

 

The Agreement shall
not become effective or enforceable until the expiration of the seven (7) day revocation period following the execution of this
release.

 

	EXECUTIVE	 	 
	 	 	 
	Dennis D.
    Cirucci	 	 
	 	 	 	 	 
	DATED:	 	 	

 

 

[Addendum Including Age Discrimination
Information to be Included in Final Release.]

 

    	- 2 -

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00242-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00242-of-00352.parquet"}]]